Unnamed: 0 float64 0 700k | Date stringlengths 23 23 | Article_title stringlengths 1 250 | Stock_symbol stringlengths 1 5 | Url stringlengths 44 135 | Publisher float64 | Author float64 | Article stringlengths 1 343k ⌀ | Lsa_summary stringlengths 48 53.9k ⌀ | Luhn_summary stringlengths 1 53.9k ⌀ | Textrank_summary stringlengths 1 53.9k ⌀ | Lexrank_summary stringlengths 1 53.9k ⌀ |
|---|---|---|---|---|---|---|---|---|---|---|---|
22,600 | 2023-04-27 00:00:00 UTC | US STOCKS-Wall St rallies as Meta earnings offset economy worries | ABBV | https://www.nasdaq.com/articles/us-stocks-wall-st-rallies-as-meta-earnings-offset-economy-worries | null | null | For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window.
Lower inventories restrains Q1 US economic growth
Meta up, touts AI might as digital ads boost outlook
Eli Lilly up on annual profit forecast raise
Amazon.com earnings due after market close
Indexes up: Dow 0.75%... | AbbVie Inc ABBV.N fell 8.1% after the drugmaker missed quarterly revenue estimates for its newer treatments, while heavy machinery maker Caterpillar Inc CAT.N dipped almost 3% as a flat order backlog signaled demand may have peaked. Lower inventories restrains Q1 US economic growth Meta up, touts AI might as digital ad... | AbbVie Inc ABBV.N fell 8.1% after the drugmaker missed quarterly revenue estimates for its newer treatments, while heavy machinery maker Caterpillar Inc CAT.N dipped almost 3% as a flat order backlog signaled demand may have peaked. Lower inventories restrains Q1 US economic growth Meta up, touts AI might as digital ad... | AbbVie Inc ABBV.N fell 8.1% after the drugmaker missed quarterly revenue estimates for its newer treatments, while heavy machinery maker Caterpillar Inc CAT.N dipped almost 3% as a flat order backlog signaled demand may have peaked. Lower inventories restrains Q1 US economic growth Meta up, touts AI might as digital ad... | AbbVie Inc ABBV.N fell 8.1% after the drugmaker missed quarterly revenue estimates for its newer treatments, while heavy machinery maker Caterpillar Inc CAT.N dipped almost 3% as a flat order backlog signaled demand may have peaked. Lower inventories restrains Q1 US economic growth Meta up, touts AI might as digital ad... |
22,601 | 2023-04-27 00:00:00 UTC | ABBV Makes Notable Cross Below Critical Moving Average | ABBV | https://www.nasdaq.com/articles/abbv-makes-notable-cross-below-critical-moving-average | null | null | In trading on Thursday, shares of AbbVie Inc (Symbol: ABBV) crossed below their 200 day moving average of $150.76, changing hands as low as $147.51 per share. AbbVie Inc shares are currently trading off about 8.6% on the day. The chart below shows the one year performance of ABBV shares, versus its 200 day moving avera... | In trading on Thursday, shares of AbbVie Inc (Symbol: ABBV) crossed below their 200 day moving average of $150.76, changing hands as low as $147.51 per share. The chart below shows the one year performance of ABBV shares, versus its 200 day moving average: Looking at the chart above, ABBV's low point in its 52 week ran... | In trading on Thursday, shares of AbbVie Inc (Symbol: ABBV) crossed below their 200 day moving average of $150.76, changing hands as low as $147.51 per share. The chart below shows the one year performance of ABBV shares, versus its 200 day moving average: Looking at the chart above, ABBV's low point in its 52 week ran... | In trading on Thursday, shares of AbbVie Inc (Symbol: ABBV) crossed below their 200 day moving average of $150.76, changing hands as low as $147.51 per share. The chart below shows the one year performance of ABBV shares, versus its 200 day moving average: Looking at the chart above, ABBV's low point in its 52 week ran... | In trading on Thursday, shares of AbbVie Inc (Symbol: ABBV) crossed below their 200 day moving average of $150.76, changing hands as low as $147.51 per share. AbbVie Inc shares are currently trading off about 8.6% on the day. The chart below shows the one year performance of ABBV shares, versus its 200 day moving avera... |
22,602 | 2023-04-27 00:00:00 UTC | AbbVie misses sales estimates for some drugs, shares tumble | ABBV | https://www.nasdaq.com/articles/abbvie-misses-sales-estimates-for-some-drugs-shares-tumble | null | null | Adds details on drug sales, shares
April 27 (Reuters) - AbbVie Inc ABBV.N on Thursday missed quarterly revenue estimates for some of its major drugs, overshadowing an increased annual profit forecast and driving shares down 5% in premarket trade.
The company recorded $3.54 billion in sales of its blockbuster drug Humir... | Adds details on drug sales, shares April 27 (Reuters) - AbbVie Inc ABBV.N on Thursday missed quarterly revenue estimates for some of its major drugs, overshadowing an increased annual profit forecast and driving shares down 5% in premarket trade. The drugmaker had been hoping that newer immunology drugs Skyrizi and Rin... | Adds details on drug sales, shares April 27 (Reuters) - AbbVie Inc ABBV.N on Thursday missed quarterly revenue estimates for some of its major drugs, overshadowing an increased annual profit forecast and driving shares down 5% in premarket trade. The company recorded $3.54 billion in sales of its blockbuster drug Humir... | Adds details on drug sales, shares April 27 (Reuters) - AbbVie Inc ABBV.N on Thursday missed quarterly revenue estimates for some of its major drugs, overshadowing an increased annual profit forecast and driving shares down 5% in premarket trade. The company recorded $3.54 billion in sales of its blockbuster drug Humir... | Adds details on drug sales, shares April 27 (Reuters) - AbbVie Inc ABBV.N on Thursday missed quarterly revenue estimates for some of its major drugs, overshadowing an increased annual profit forecast and driving shares down 5% in premarket trade. The company recorded $3.54 billion in sales of its blockbuster drug Humir... |
22,603 | 2023-04-27 00:00:00 UTC | S&P 500 Movers: ALGN, META | ABBV | https://www.nasdaq.com/articles/sp-500-movers%3A-algn-meta | null | null | In early trading on Thursday, shares of Meta Platforms topped the list of the day's best performing components of the S&P 500 index, trading up 14.7%. Year to date, Meta Platforms registers a 99.6% gain.
And the worst performing S&P 500 component thus far on the day is Align Technology, trading down 11.1%. Align Techno... | Two other components making moves today are AbbVie, trading down 8.6%, and Hasbro, trading up 10.4% on the day. Year to date, Meta Platforms registers a 99.6% gain. And the worst performing S&P 500 component thus far on the day is Align Technology, trading down 11.1%. | Two other components making moves today are AbbVie, trading down 8.6%, and Hasbro, trading up 10.4% on the day. In early trading on Thursday, shares of Meta Platforms topped the list of the day's best performing components of the S&P 500 index, trading up 14.7%. Year to date, Meta Platforms registers a 99.6% gain. | Two other components making moves today are AbbVie, trading down 8.6%, and Hasbro, trading up 10.4% on the day. In early trading on Thursday, shares of Meta Platforms topped the list of the day's best performing components of the S&P 500 index, trading up 14.7%. And the worst performing S&P 500 component thus far on th... | Two other components making moves today are AbbVie, trading down 8.6%, and Hasbro, trading up 10.4% on the day. In early trading on Thursday, shares of Meta Platforms topped the list of the day's best performing components of the S&P 500 index, trading up 14.7%. And the worst performing S&P 500 component thus far on th... |
22,604 | 2023-04-27 00:00:00 UTC | Drugmakers post healthy results as growth drivers shine | ABBV | https://www.nasdaq.com/articles/drugmakers-post-healthy-results-as-growth-drivers-shine | null | null | April 27 (Reuters) - Drugmakers including Merck & Co MRK.N, Eli Lilly LLY.N and AstraZeneca Plc AZN.L reported strong first-quarter earnings and several raised their expectations for 2023, as post-pandemic demand for cancer and other treatments jumped.
The earnings on Thursday shine a spotlight on the pharmaceuticals s... | AbbVie ABBV.N reported first-quarter sales that missed estimates for most treatments, including for blockbuster therapy Humira. AbbVie shares were down 6.2% after sales of newer treatments Rinvoq and Skyrizi, which it has been hoping will fill the gap of Humira's sales, missed expectations. April 27 (Reuters) - Drugmak... | AbbVie ABBV.N reported first-quarter sales that missed estimates for most treatments, including for blockbuster therapy Humira. AbbVie shares were down 6.2% after sales of newer treatments Rinvoq and Skyrizi, which it has been hoping will fill the gap of Humira's sales, missed expectations. April 27 (Reuters) - Drugmak... | AbbVie ABBV.N reported first-quarter sales that missed estimates for most treatments, including for blockbuster therapy Humira. AbbVie shares were down 6.2% after sales of newer treatments Rinvoq and Skyrizi, which it has been hoping will fill the gap of Humira's sales, missed expectations. April 27 (Reuters) - Drugmak... | AbbVie ABBV.N reported first-quarter sales that missed estimates for most treatments, including for blockbuster therapy Humira. AbbVie shares were down 6.2% after sales of newer treatments Rinvoq and Skyrizi, which it has been hoping will fill the gap of Humira's sales, missed expectations. April 27 (Reuters) - Drugmak... |
22,605 | 2023-04-27 00:00:00 UTC | Health Care Sector Update for 04/27/2023: ABBV, MRK, AZN, XLV, IBB | ABBV | https://www.nasdaq.com/articles/health-care-sector-update-for-04-27-2023%3A-abbv-mrk-azn-xlv-ibb | null | null | Health care stocks were narrowly mixed pre-bell Thursday. The Health Care Select Sector SPDR Fund (XLV) was 0.2% higher and the iShares Biotechnology ETF (IBB) was marginally lower.
AbbVie (ABBV) was declining by more than 3% after it reported Q1 adjusted earnings of $2.46 per diluted share, compared with $3.16 a year ... | AbbVie (ABBV) was declining by more than 3% after it reported Q1 adjusted earnings of $2.46 per diluted share, compared with $3.16 a year earlier. The Health Care Select Sector SPDR Fund (XLV) was 0.2% higher and the iShares Biotechnology ETF (IBB) was marginally lower. AstraZeneca (AZN) was advancing 0.4% after it rep... | AbbVie (ABBV) was declining by more than 3% after it reported Q1 adjusted earnings of $2.46 per diluted share, compared with $3.16 a year earlier. Analysts polled by Capital IQ expected $2.48. Analysts polled by Capital IQ expected $1.70. | AbbVie (ABBV) was declining by more than 3% after it reported Q1 adjusted earnings of $2.46 per diluted share, compared with $3.16 a year earlier. The Health Care Select Sector SPDR Fund (XLV) was 0.2% higher and the iShares Biotechnology ETF (IBB) was marginally lower. Merck (MRK) was up over 2% after saying it now ex... | AbbVie (ABBV) was declining by more than 3% after it reported Q1 adjusted earnings of $2.46 per diluted share, compared with $3.16 a year earlier. Health care stocks were narrowly mixed pre-bell Thursday. The Health Care Select Sector SPDR Fund (XLV) was 0.2% higher and the iShares Biotechnology ETF (IBB) was marginall... |
22,606 | 2023-04-27 00:00:00 UTC | AbbVie (ABBV) Q1 Earnings and Revenues Top Estimates | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-q1-earnings-and-revenues-top-estimates | null | null | AbbVie (ABBV) came out with quarterly earnings of $2.46 per share, beating the Zacks Consensus Estimate of $2.44 per share. This compares to earnings of $3.16 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of 0.82%. A quarter ago, it was e... | AbbVie (ABBV) came out with quarterly earnings of $2.46 per share, beating the Zacks Consensus Estimate of $2.44 per share. AbbVie, which belongs to the Zacks Large Cap Pharmaceuticals industry, posted revenues of $12.23 billion for the quarter ended March 2023, surpassing the Zacks Consensus Estimate by 1.17%. AbbVie ... | AbbVie, which belongs to the Zacks Large Cap Pharmaceuticals industry, posted revenues of $12.23 billion for the quarter ended March 2023, surpassing the Zacks Consensus Estimate by 1.17%. Click to get this free report AbbVie Inc. (ABBV) : Free Stock Analysis Report Prometheus Biosciences, Inc. (RXDX) : Free Stock Anal... | AbbVie (ABBV) came out with quarterly earnings of $2.46 per share, beating the Zacks Consensus Estimate of $2.44 per share. AbbVie, which belongs to the Zacks Large Cap Pharmaceuticals industry, posted revenues of $12.23 billion for the quarter ended March 2023, surpassing the Zacks Consensus Estimate by 1.17%. Click t... | AbbVie (ABBV) came out with quarterly earnings of $2.46 per share, beating the Zacks Consensus Estimate of $2.44 per share. AbbVie, which belongs to the Zacks Large Cap Pharmaceuticals industry, posted revenues of $12.23 billion for the quarter ended March 2023, surpassing the Zacks Consensus Estimate by 1.17%. AbbVie ... |
22,607 | 2023-04-27 00:00:00 UTC | 1 Dividend Stock to Buy Hand Over Fist in May and 1 to Avoid | ABBV | https://www.nasdaq.com/articles/1-dividend-stock-to-buy-hand-over-fist-in-may-and-1-to-avoid | null | null | Some dividend stocks will pay a tidy and ever-increasing sum into your account for years. Others will run out of steam and slash your quarterly paycheck. Ideally, you'd buy shares of the first kind and avoid the second kind. So here's one example of each.
Image source: Getty Images.
1. AbbVie
AbbVie (NYSE: ABBV) is a m... | Thanks to its colossal drug development pipeline with more than 240 different ongoing clinical trials, and a portfolio of marketed medicines borne from 25 major regulatory approvals since its inception in 2013, AbbVie has both a track record of success and a long future of likely growth ahead. AbbVie AbbVie (NYSE: ABBV... | AbbVie AbbVie (NYSE: ABBV) is a major pharmaceutical company that's also a majorly appealing dividend stock. Thanks to its colossal drug development pipeline with more than 240 different ongoing clinical trials, and a portfolio of marketed medicines borne from 25 major regulatory approvals since its inception in 2013, ... | AbbVie AbbVie (NYSE: ABBV) is a major pharmaceutical company that's also a majorly appealing dividend stock. As AbbVie's payout ratio is near 85% of its 2022 annual earnings of $11.8 billion, there's still some room for the dividend to grow in the absence of earnings growth. Thanks to its colossal drug development pipe... | * They just revealed what they believe are the ten best stocks for investors to buy right now... and AbbVie wasn't one of them! AbbVie AbbVie (NYSE: ABBV) is a major pharmaceutical company that's also a majorly appealing dividend stock. Thanks to its colossal drug development pipeline with more than 240 different ongoi... |
22,608 | 2023-04-27 00:00:00 UTC | AbbVie Q1 Profit Drops, Inline With Estimates | ABBV | https://www.nasdaq.com/articles/abbvie-q1-profit-drops-inline-with-estimates | null | null | (RTTNews) - AbbVie (ABBV) reported earnings for first quarter that decreased from last year in line with the Street estimates.
The company's earnings totaled $239 million, or $0.13 per share. This compares with $4.49 billion, or $2.51 per share, in last year's first quarter.
Excluding items, AbbVie reported adjusted ea... | (RTTNews) - AbbVie (ABBV) reported earnings for first quarter that decreased from last year in line with the Street estimates. Excluding items, AbbVie reported adjusted earnings of $4.39 billion or $2.46 per share for the period. AbbVie earnings at a glance (GAAP) : -Earnings (Q1): $239 Mln. | Excluding items, AbbVie reported adjusted earnings of $4.39 billion or $2.46 per share for the period. (RTTNews) - AbbVie (ABBV) reported earnings for first quarter that decreased from last year in line with the Street estimates. AbbVie earnings at a glance (GAAP) : -Earnings (Q1): $239 Mln. | (RTTNews) - AbbVie (ABBV) reported earnings for first quarter that decreased from last year in line with the Street estimates. Excluding items, AbbVie reported adjusted earnings of $4.39 billion or $2.46 per share for the period. AbbVie earnings at a glance (GAAP) : -Earnings (Q1): $239 Mln. | Excluding items, AbbVie reported adjusted earnings of $4.39 billion or $2.46 per share for the period. (RTTNews) - AbbVie (ABBV) reported earnings for first quarter that decreased from last year in line with the Street estimates. AbbVie earnings at a glance (GAAP) : -Earnings (Q1): $239 Mln. |
22,609 | 2023-04-27 00:00:00 UTC | AbbVie raises annual profit forecast as Humira demand holds steady | ABBV | https://www.nasdaq.com/articles/abbvie-raises-annual-profit-forecast-as-humira-demand-holds-steady | null | null | Adds missing words in headline
April 27 (Reuters) - AbbVie Inc ABBV.N on Thursday raised its 2023 profit forecast on a less-than-feared hit to U.S. sales of arthritis drug Humira from rival biosimilar drugs.
The company now expects 2023 adjusted earnings to be between $10.72 and $11.12 per share, from between $10.62 an... | Adds missing words in headline April 27 (Reuters) - AbbVie Inc ABBV.N on Thursday raised its 2023 profit forecast on a less-than-feared hit to U.S. sales of arthritis drug Humira from rival biosimilar drugs. The company now expects 2023 adjusted earnings to be between $10.72 and $11.12 per share, from between $10.62 an... | Adds missing words in headline April 27 (Reuters) - AbbVie Inc ABBV.N on Thursday raised its 2023 profit forecast on a less-than-feared hit to U.S. sales of arthritis drug Humira from rival biosimilar drugs. Analysts on average have estimated annual adjusted profit of $10.94 per share, according to Refinitiv IBES data.... | Adds missing words in headline April 27 (Reuters) - AbbVie Inc ABBV.N on Thursday raised its 2023 profit forecast on a less-than-feared hit to U.S. sales of arthritis drug Humira from rival biosimilar drugs. Analysts on average have estimated annual adjusted profit of $10.94 per share, according to Refinitiv IBES data.... | Adds missing words in headline April 27 (Reuters) - AbbVie Inc ABBV.N on Thursday raised its 2023 profit forecast on a less-than-feared hit to U.S. sales of arthritis drug Humira from rival biosimilar drugs. The company now expects 2023 adjusted earnings to be between $10.72 and $11.12 per share, from between $10.62 an... |
22,610 | 2023-04-27 00:00:00 UTC | SPYG, CVX, MRK, ABBV: ETF Inflow Alert | ABBV | https://www.nasdaq.com/articles/spyg-cvx-mrk-abbv%3A-etf-inflow-alert | null | null | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR Portfolio S&P 500 Growth ETF (Symbol: SPYG) where we have detected an approximate $199.9 million dollar inflow -- that's a 1.3% increase week over week in outstanding units (from 288,80... | Among the largest underlying components of SPYG, in trading today Chevron Corporation (Symbol: CVX) is up about 0.1%, Merck & Co Inc (Symbol: MRK) is down about 1.9%, and AbbVie Inc (Symbol: ABBV) is lower by about 8.2%. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed... | Among the largest underlying components of SPYG, in trading today Chevron Corporation (Symbol: CVX) is up about 0.1%, Merck & Co Inc (Symbol: MRK) is down about 1.9%, and AbbVie Inc (Symbol: ABBV) is lower by about 8.2%. For a complete list of holdings, visit the SPYG Holdings page » The chart below shows the one year ... | Among the largest underlying components of SPYG, in trading today Chevron Corporation (Symbol: CVX) is up about 0.1%, Merck & Co Inc (Symbol: MRK) is down about 1.9%, and AbbVie Inc (Symbol: ABBV) is lower by about 8.2%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ET... | Among the largest underlying components of SPYG, in trading today Chevron Corporation (Symbol: CVX) is up about 0.1%, Merck & Co Inc (Symbol: MRK) is down about 1.9%, and AbbVie Inc (Symbol: ABBV) is lower by about 8.2%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ET... |
22,611 | 2023-04-26 00:00:00 UTC | Drug/Biotech Stocks' Q1 Earnings Due Apr 27: LLY, ABBV & More | ABBV | https://www.nasdaq.com/articles/drug-biotech-stocks-q1-earnings-due-apr-27%3A-lly-abbv-more | null | null | The first-quarter 2023 reporting cycle of the Medical sector is about to pick up pace this week. The sector mainly comprises pharma/biotech and medical device companies.
The earnings season for the Medical sector kicked off last week when bellwether Johnson & Johnson reported better-than-expected first-quarter results.... | Eli Lilly LLY, AbbVie ABBV, Bristol Myers BMY, Merck MRK and Gilead Sciences GILD are scheduled to release first-quarter earnings on Apr 27. AbbVie’s top line is expected to have been driven by sales of new immunology drugs, Skyrizi and Rinvoq, which registered strong growth in the past few quarters. While LLY, ABBV, B... | Eli Lilly and Company Price and EPS Surprise Eli Lilly and Company price-eps-surprise | Eli Lilly and Company Quote AbbVie AbbVie has an encouraging earnings track record to date. Click to get this free report Bristol Myers Squibb Company (BMY) : Free Stock Analysis Report Merck & Co., Inc. (MRK) : Free Stock Analysis ... | Click to get this free report Bristol Myers Squibb Company (BMY) : Free Stock Analysis Report Merck & Co., Inc. (MRK) : Free Stock Analysis Report Eli Lilly and Company (LLY) : Free Stock Analysis Report Gilead Sciences, Inc. (GILD) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report To read th... | In the last reported quarter, AbbVie’s earnings beat estimates by 1.69%. Eli Lilly LLY, AbbVie ABBV, Bristol Myers BMY, Merck MRK and Gilead Sciences GILD are scheduled to release first-quarter earnings on Apr 27. While LLY, ABBV, BMY and MRK are set to report before the opening bell, GILD will report after market clos... |
22,612 | 2023-04-26 00:00:00 UTC | Guru Fundamental Report for ABBV | ABBV | https://www.nasdaq.com/articles/guru-fundamental-report-for-abbv-19 | null | null | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the ... | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the ... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanr... |
22,613 | 2023-04-26 00:00:00 UTC | Earnings Beat In The Cards For Merck Stock? | ABBV | https://www.nasdaq.com/articles/earnings-beat-in-the-cards-for-merck-stock | null | null | Merck (NYSE: MRK) will report its Q1 2023 results on Thursday, April 27. We expect MRK stock to trade higher, with its revenue and earnings expected to be above the street estimates. Although the company should benefit from continued market share gains for Keytruda and Gardasil, among other products, forex headwinds an... | Although the company should benefit from continued market share gains for Keytruda and Gardasil, among other products, forex headwinds and generic competition for some of its drugs, including Januvia/Janumet, may weigh on its overall performance. Merck’s diabetes drugs – Januvia/Janumet – now face generic competition i... | (1) Revenues expected to be above the consensus estimates Trefis estimates Merck’s Q1 2023 revenues to be $13.9 billion, reflecting a 13% y-o-y decline and slightly above the $13.8 billion consensus estimate. Looking at Q4 2022, Merck reported revenue of $13.8 billion, reflecting a 2% y-o-y growth, driven by a 19% rise... | (1) Revenues expected to be above the consensus estimates Trefis estimates Merck’s Q1 2023 revenues to be $13.9 billion, reflecting a 13% y-o-y decline and slightly above the $13.8 billion consensus estimate. Looking at Q4 2022, Merck reported revenue of $13.8 billion, reflecting a 2% y-o-y growth, driven by a 19% rise... | This compares with the $2.14 figure the company reported in the prior-year quarter. (3) MRK stock is fully valued We estimate Merck’s Valuation to be $116 per share, aligning with its current market price. Total [2] MRK Return 9% 4% 97% S&P 500 Return 1% 8% 85% Trefis Multi-Strategy Portfolio 1% 9% 244% [1] Month-to-da... |
22,614 | 2023-04-25 00:00:00 UTC | This Supercharged Dividend King Stock Might Soon Run Out of Steam | ABBV | https://www.nasdaq.com/articles/this-supercharged-dividend-king-stock-might-soon-run-out-of-steam | null | null | AbbVie (NYSE: ABBV) has been a top growth and passive-income machine for investors since splitting off from parent company Abbott Laboratories (NYSE: ABT) in 2013. Speaking to this point, the drugmaker has grown its annual revenue by a healthy 215% and its dividend payout by 270% since becoming an independent entity.
A... | While some of these rivals have carved out a profitable niche in this $200-billion-a-year space, AbbVie has nonetheless maintained a top-shelf market share in several key indications, such as rheumatoid arthritis and inflammatory bowel disease (IBD), among others. AbbVie (NYSE: ABBV) has been a top growth and passive-i... | While some of these rivals have carved out a profitable niche in this $200-billion-a-year space, AbbVie has nonetheless maintained a top-shelf market share in several key indications, such as rheumatoid arthritis and inflammatory bowel disease (IBD), among others. AbbVie (NYSE: ABBV) has been a top growth and passive-i... | As a result of its rapid top-line growth and ever-rising dividend payout, AbbVie has been one of the best-performing Dividend King stocks over the past 10 years. AbbVie's success has centered around the anti-inflammatory biologic medicine Humira, which has topped $20 billion in annual sales each of the past three years... | As a result of its rapid top-line growth and ever-rising dividend payout, AbbVie has been one of the best-performing Dividend King stocks over the past 10 years. Like Imbruvica, Botox has been a key growth product for AbbVie since this transaction. AbbVie (NYSE: ABBV) has been a top growth and passive-income machine fo... |
22,615 | 2023-04-25 00:00:00 UTC | Health Care Sector Update for 04/25/2023: ENTA, ABBV, TCON, IMAB, BIIB, ABUS | ABBV | https://www.nasdaq.com/articles/health-care-sector-update-for-04-25-2023%3A-enta-abbv-tcon-imab-biib-abus | null | null | Health care stocks were lower late Tuesday afternoon, with the NYSE Health Care Index falling 0.7% and the Health Care Select Sector SPDR Fund (XLV) down 1.1%.
The iShares Biotechnology ETF (IBB) was decreasing 1.9%.
In company news, Enanta Pharmaceuticals (ENTA) said it sold its 54.5% of future royalty payments from A... | In company news, Enanta Pharmaceuticals (ENTA) said it sold its 54.5% of future royalty payments from AbbVie (ABBV) on global sales of Mavyret/Maviret to OMERS, a Canadian pension fund, for $200 million. Tracon Pharmaceuticals (TCON) shares dropped 47% after the company said the tribunal in the arbitration against I-Ma... | In company news, Enanta Pharmaceuticals (ENTA) said it sold its 54.5% of future royalty payments from AbbVie (ABBV) on global sales of Mavyret/Maviret to OMERS, a Canadian pension fund, for $200 million. Health care stocks were lower late Tuesday afternoon, with the NYSE Health Care Index falling 0.7% and the Health Ca... | In company news, Enanta Pharmaceuticals (ENTA) said it sold its 54.5% of future royalty payments from AbbVie (ABBV) on global sales of Mavyret/Maviret to OMERS, a Canadian pension fund, for $200 million. Health care stocks were lower late Tuesday afternoon, with the NYSE Health Care Index falling 0.7% and the Health Ca... | In company news, Enanta Pharmaceuticals (ENTA) said it sold its 54.5% of future royalty payments from AbbVie (ABBV) on global sales of Mavyret/Maviret to OMERS, a Canadian pension fund, for $200 million. Enanta shares were down 4.4%. I-Mab shares were down 1.6%. |
22,616 | 2023-04-25 00:00:00 UTC | Is Global X SuperDividend U.S. ETF (DIV) a Strong ETF Right Now? | ABBV | https://www.nasdaq.com/articles/is-global-x-superdividend-u.s.-etf-div-a-strong-etf-right-now-7 | null | null | Launched on 03/11/2013, the Global X SuperDividend U.S. ETF (DIV) is a smart beta exchange traded fund offering broad exposure to the Style Box - All Cap Value category of the market.
What Are Smart Beta ETFs?
For a long time now, the ETF industry has been flooded with products based on market capitalization weighted i... | When you look at individual holdings, B&g Foods Inc (BGS) accounts for about 2.71% of the fund's total assets, followed by San Juan Basin Royalty Tr (SJT) and Abbvie Inc (ABBV). Click to get this free report Global X SuperDividend U.S. ETF (DIV): ETF Research Reports B&G Foods, Inc. (BGS) : Free Stock Analysis Report A... | Click to get this free report Global X SuperDividend U.S. ETF (DIV): ETF Research Reports B&G Foods, Inc. (BGS) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report Global X SuperDividend ETF (SDIV): ETF Research Reports WBI Power Factor High Dividend ETF (WBIY): ETF Research Reports San Juan Ba... | Click to get this free report Global X SuperDividend U.S. ETF (DIV): ETF Research Reports B&G Foods, Inc. (BGS) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report Global X SuperDividend ETF (SDIV): ETF Research Reports WBI Power Factor High Dividend ETF (WBIY): ETF Research Reports San Juan Ba... | When you look at individual holdings, B&g Foods Inc (BGS) accounts for about 2.71% of the fund's total assets, followed by San Juan Basin Royalty Tr (SJT) and Abbvie Inc (ABBV). Click to get this free report Global X SuperDividend U.S. ETF (DIV): ETF Research Reports B&G Foods, Inc. (BGS) : Free Stock Analysis Report A... |
22,617 | 2023-04-25 00:00:00 UTC | Should SPDR Portfolio S&P 500 High Dividend ETF (SPYD) Be on Your Investing Radar? | ABBV | https://www.nasdaq.com/articles/should-spdr-portfolio-sp-500-high-dividend-etf-spyd-be-on-your-investing-radar-6 | null | null | Looking for broad exposure to the Large Cap Value segment of the US equity market? You should consider the SPDR Portfolio S&P 500 High Dividend ETF (SPYD), a passively managed exchange traded fund launched on 10/21/2015.
The fund is sponsored by State Street Global Advisors. It has amassed assets over $6.77 billion, ma... | Looking at individual holdings, Abbvie Inc. (ABBV) accounts for about 1.50% of total assets, followed by Pinnacle West Capital Corporation (PNW) and Packaging Corporation Of America (PKG). Click to get this free report SPDR Portfolio S&P 500 High Dividend ETF (SPYD): ETF Research Reports Pinnacle West Capital Corporati... | Looking at individual holdings, Abbvie Inc. (ABBV) accounts for about 1.50% of total assets, followed by Pinnacle West Capital Corporation (PNW) and Packaging Corporation Of America (PKG). Click to get this free report SPDR Portfolio S&P 500 High Dividend ETF (SPYD): ETF Research Reports Pinnacle West Capital Corporati... | Click to get this free report SPDR Portfolio S&P 500 High Dividend ETF (SPYD): ETF Research Reports Pinnacle West Capital Corporation (PNW) : Free Stock Analysis Report Packaging Corporation of America (PKG) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report Vanguard Value ETF (VTV): ETF Resea... | Click to get this free report SPDR Portfolio S&P 500 High Dividend ETF (SPYD): ETF Research Reports Pinnacle West Capital Corporation (PNW) : Free Stock Analysis Report Packaging Corporation of America (PKG) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report Vanguard Value ETF (VTV): ETF Resea... |
22,618 | 2023-04-24 00:00:00 UTC | Guru Fundamental Report for ABBV | ABBV | https://www.nasdaq.com/articles/guru-fundamental-report-for-abbv-18 | null | null | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the ... | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the ... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanr... |
22,619 | 2023-04-24 00:00:00 UTC | Can Amgen (AMGN) Keep the Earnings Streak Alive in Q1? | ABBV | https://www.nasdaq.com/articles/can-amgen-amgn-keep-the-earnings-streak-alive-in-q1 | null | null | We expect Amgen AMGN to beat expectations when it reports first-quarter 2023 results on Apr 27, after market close. In the last reported quarter, the company delivered an earnings surprise of 1.24%.
This large biotech’s performance has been strong, with earnings beating estimates in all the trailing four quarters. The ... | In January, Amgen launched Amjevita in the United States at a list price 55% below the current list price set by AbbVie ABBV for Humira. Amgen is the first company to have launched a biosimilar of AbbVie’s Humira in the United States. Amgen already markets a biosimilar of AbbVie’s Humira, Amgevita, outside the United S... | Click to get this free report AstraZeneca PLC (AZN) : Free Stock Analysis Report Novo Nordisk A/S (NVO) : Free Stock Analysis Report Amgen Inc. (AMGN) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report To read this article on Zacks.com click here. In January, Amgen launched Amjevita in the Uni... | Click to get this free report AstraZeneca PLC (AZN) : Free Stock Analysis Report Novo Nordisk A/S (NVO) : Free Stock Analysis Report Amgen Inc. (AMGN) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report To read this article on Zacks.com click here. In January, Amgen launched Amjevita in the Uni... | In January, Amgen launched Amjevita in the United States at a list price 55% below the current list price set by AbbVie ABBV for Humira. Amgen is the first company to have launched a biosimilar of AbbVie’s Humira in the United States. Amgen already markets a biosimilar of AbbVie’s Humira, Amgevita, outside the United S... |
22,620 | 2023-04-24 00:00:00 UTC | AbbVie (ABBV) to Report Q1 Earnings: What's in the Cards? | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-to-report-q1-earnings%3A-whats-in-the-cards | null | null | AbbVie ABBV will report first-quarter 2023 results on Apr 27, before market open. In the last reported quarter, the company delivered an earnings surprise of 1.69%.
This large drugmaker’s performance has been impressive, with its earnings beating estimates in each of the trailing four quarters. The company has a traili... | Factors to Consider AbbVie’s top line is expected to have been driven by sales of new immunology drugs, Skyrizi and Rinvoq, which registered strong growth in the past few quarters. AbbVie ABBV will report first-quarter 2023 results on Apr 27, before market open. AbbVie’s shares have inched up 0.5% so far this year comp... | AbbVie markets Imbruvica in partnership with Johnson & Johnson JNJ and Venclexta in partnership with Roche RHHBY. Click to get this free report Roche Holding AG (RHHBY) : Free Stock Analysis Report Johnson & Johnson (JNJ) : Free Stock Analysis Report Novo Nordisk A/S (NVO) : Free Stock Analysis Report AbbVie Inc. (ABBV... | Earnings ESP: AbbVie has an Earnings ESP of -1.13% as the Most Accurate Estimate of $2.44 per share is lower than the Zacks Consensus Estimate of $2.46. Click to get this free report Roche Holding AG (RHHBY) : Free Stock Analysis Report Johnson & Johnson (JNJ) : Free Stock Analysis Report Novo Nordisk A/S (NVO) : Free ... | Earnings ESP: AbbVie has an Earnings ESP of -1.13% as the Most Accurate Estimate of $2.44 per share is lower than the Zacks Consensus Estimate of $2.46. AbbVie ABBV will report first-quarter 2023 results on Apr 27, before market open. AbbVie’s shares have inched up 0.5% so far this year compared with the industry’s 3.3... |
22,621 | 2023-04-23 00:00:00 UTC | The Best Stocks to Invest $20,000 in Right Now | ABBV | https://www.nasdaq.com/articles/the-best-stocks-to-invest-%2420000-in-right-now-5 | null | null | If you have $20,000 to invest, you could put it all in one stock -- or you could invest across several. I favor buying a few stocks that can each offer you something different. For instance, one may pay you a top-notch dividend, another may offer you a solid track record of earnings growth, and a third might promise th... | AbbVie AbbVie (NYSE: ABBV) is a stock you'll like for its earnings and dividend growth over time. Today, AbbVie's top immunology drug, Humira, is losing exclusivity, but the good news is AbbVie has two other immunology drugs set to compensate -- and extend growth. In fact, AbbVie forecasts that by 2027, Rinvoq and Skyr... | Today, AbbVie's top immunology drug, Humira, is losing exclusivity, but the good news is AbbVie has two other immunology drugs set to compensate -- and extend growth. AbbVie AbbVie (NYSE: ABBV) is a stock you'll like for its earnings and dividend growth over time. In fact, AbbVie forecasts that by 2027, Rinvoq and Skyr... | AbbVie AbbVie (NYSE: ABBV) is a stock you'll like for its earnings and dividend growth over time. And AbbVie's policy of raising its dividend year after year suggests your passive income might grow over time if you invest in this top stock. Today, AbbVie's top immunology drug, Humira, is losing exclusivity, but the goo... | AbbVie AbbVie (NYSE: ABBV) is a stock you'll like for its earnings and dividend growth over time. Today, AbbVie's top immunology drug, Humira, is losing exclusivity, but the good news is AbbVie has two other immunology drugs set to compensate -- and extend growth. In fact, AbbVie forecasts that by 2027, Rinvoq and Skyr... |
22,622 | 2023-04-22 00:00:00 UTC | 3 Top Dividend Kings to Buy for the Long Haul | ABBV | https://www.nasdaq.com/articles/3-top-dividend-kings-to-buy-for-the-long-haul-7 | null | null | Investing in Dividend Kings is just one part of a solid long-term strategy. The attraction is that their long history of annual dividend increases (50 consecutive years or more) reflects well on the companies' business growth and stability.
That doesn't mean that they won't see their shares jump or fall; they're not im... | Johnson & Johnson (NYSE: JNJ), AbbVie (NYSE: ABBV), and Embecta (NASDAQ: EMBC.V) are Dividend Kings that represent good long-term investments. Over the past 10 years, the company has grown annual revenue by 33%, well below the 209% that AbbVie has in that time. AbbVie will rebound quickly Counting its time before 2013 ... | Johnson & Johnson (NYSE: JNJ), AbbVie (NYSE: ABBV), and Embecta (NASDAQ: EMBC.V) are Dividend Kings that represent good long-term investments. AbbVie will rebound quickly Counting its time before 2013 as part of Abbott Laboratories, AbbVie has raised its dividend for 51 consecutive years, including a boost of 5% this y... | AbbVie's blockbuster immunology drug Humira brought in $21.2 billion last year, but the company said it expects its sales to decline 37% this year, thanks to the introduction of biosimilar competition in the United States. Johnson & Johnson (NYSE: JNJ), AbbVie (NYSE: ABBV), and Embecta (NASDAQ: EMBC.V) are Dividend Kin... | Over the past 10 years, the company has grown annual revenue by 33%, well below the 209% that AbbVie has in that time. Johnson & Johnson (NYSE: JNJ), AbbVie (NYSE: ABBV), and Embecta (NASDAQ: EMBC.V) are Dividend Kings that represent good long-term investments. AbbVie will rebound quickly Counting its time before 2013 ... |
22,623 | 2023-04-21 00:00:00 UTC | Noteworthy Friday Option Activity: ABBV, PEN, DE | ABBV | https://www.nasdaq.com/articles/noteworthy-friday-option-activity%3A-abbv-pen-de | null | null | Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in AbbVie Inc (Symbol: ABBV), where a total of 21,236 contracts have traded so far, representing approximately 2.1 million underlying shares. That amounts to about 50.2% of ABBV's average daily trading volume over ... | Especially high volume was seen for the $175 strike call option expiring January 19, 2024, with 2,690 contracts trading so far today, representing approximately 269,000 underlying shares of ABBV. Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in AbbVie Inc (Sym... | Below is a chart showing ABBV's trailing twelve month trading history, with the $175 strike highlighted in orange: Penumbra Inc (Symbol: PEN) options are showing a volume of 1,543 contracts thus far today. Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in AbbVi... | Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in AbbVie Inc (Symbol: ABBV), where a total of 21,236 contracts have traded so far, representing approximately 2.1 million underlying shares. That amounts to about 50.2% of ABBV's average daily trading volume over ... | Below is a chart showing DE's trailing twelve month trading history, with the $405 strike highlighted in orange: For the various different available expirations for ABBV options, PEN options, or DE options, visit StockOptionsChannel.com. Among the underlying components of the Russell 3000 index, we saw noteworthy optio... |
22,624 | 2023-04-21 00:00:00 UTC | Pharma Stock Roundup: JNJ Beats on Q1 Earnings, MRK to Buy RXDX & Other Updates | ABBV | https://www.nasdaq.com/articles/pharma-stock-roundup%3A-jnj-beats-on-q1-earnings-mrk-to-buy-rxdx-other-updates | null | null | This week, J&J JNJ began the first-quarter earnings season for the drug and biotech sector with strong results. Merck MRK offered to buy Prometheus Biosciences RXDX for around $10.8 billion. The FDA approved AbbVie’s ABBV Qulipta for chronic migraine indication.
Recap of the Week’s Most Important Stories
J&J Begins Q1 ... | The FDA approved AbbVie’s ABBV Qulipta for chronic migraine indication. FDA Approves AbbVie’s Qulipta for Chronic Migraine: The FDA approved AbbVie’s new drug Qulipta (60 mg) for the prevention of chronic migraine in adults. The European Commission granted approval to AbbVie’s Rinvoq (upadacitinib – 15 mg and 30 mg) fo... | FDA Approves AbbVie’s Qulipta for Chronic Migraine: The FDA approved AbbVie’s new drug Qulipta (60 mg) for the prevention of chronic migraine in adults. Click to get this free report Johnson & Johnson (JNJ) : Free Stock Analysis Report Merck & Co., Inc. (MRK) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock... | FDA Approves AbbVie’s Qulipta for Chronic Migraine: The FDA approved AbbVie’s new drug Qulipta (60 mg) for the prevention of chronic migraine in adults. Click to get this free report Johnson & Johnson (JNJ) : Free Stock Analysis Report Merck & Co., Inc. (MRK) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock... | The European Commission granted approval to AbbVie’s Rinvoq (upadacitinib – 15 mg and 30 mg) for the treatment of adults with moderately to severely active Crohn's disease. The FDA approved AbbVie’s ABBV Qulipta for chronic migraine indication. FDA Approves AbbVie’s Qulipta for Chronic Migraine: The FDA approved AbbVie... |
22,625 | 2023-04-20 00:00:00 UTC | Abbvie Inc Shares Close in on 52-Week High - Market Mover | ABBV | https://www.nasdaq.com/articles/abbvie-inc-shares-close-in-on-52-week-high-market-mover-0 | null | null | Abbvie Inc (ABBV) shares closed today at 1.6% below its 52 week high of $165.01, giving the company a market cap of $285B. The stock is currently up 2.0% year-to-date, up 7.2% over the past 12 months, and up 120.6% over the past five years. This week, the Dow Jones Industrial Average fell 0.7%, and the S&P 500 fell 0.4... | Abbvie Inc (ABBV) shares closed today at 1.6% below its 52 week high of $165.01, giving the company a market cap of $285B. Beta, a measure of the stock’s volatility relative to the overall market stands at 0.4. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70. | Abbvie Inc (ABBV) shares closed today at 1.6% below its 52 week high of $165.01, giving the company a market cap of $285B. This week, the Dow Jones Industrial Average fell 0.7%, and the S&P 500 fell 0.4%. Trading Activity Trading volume this week was 10.0% lower than the 20-day average. | Abbvie Inc (ABBV) shares closed today at 1.6% below its 52 week high of $165.01, giving the company a market cap of $285B. Market Comparative Performance The company's share price is the same as the S&P 500 Index , beats it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the D... | Abbvie Inc (ABBV) shares closed today at 1.6% below its 52 week high of $165.01, giving the company a market cap of $285B. This week, the Dow Jones Industrial Average fell 0.7%, and the S&P 500 fell 0.4%. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70. |
22,626 | 2023-04-20 00:00:00 UTC | Earnings Preview: AbbVie (ABBV) Q1 Earnings Expected to Decline | ABBV | https://www.nasdaq.com/articles/earnings-preview%3A-abbvie-abbv-q1-earnings-expected-to-decline | null | null | Wall Street expects a year-over-year decline in earnings on lower revenues when AbbVie (ABBV) reports results for the quarter ended March 2023. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actua... | Wall Street expects a year-over-year decline in earnings on lower revenues when AbbVie (ABBV) reports results for the quarter ended March 2023. How Have the Numbers Shaped Up for AbbVie? For AbbVie, the Most Accurate Estimate is lower than the Zacks Consensus Estimate, suggesting that analysts have recently become bear... | Wall Street expects a year-over-year decline in earnings on lower revenues when AbbVie (ABBV) reports results for the quarter ended March 2023. How Have the Numbers Shaped Up for AbbVie? For AbbVie, the Most Accurate Estimate is lower than the Zacks Consensus Estimate, suggesting that analysts have recently become bear... | For AbbVie, the Most Accurate Estimate is lower than the Zacks Consensus Estimate, suggesting that analysts have recently become bearish on the company's earnings prospects. Wall Street expects a year-over-year decline in earnings on lower revenues when AbbVie (ABBV) reports results for the quarter ended March 2023. Ho... | For AbbVie, the Most Accurate Estimate is lower than the Zacks Consensus Estimate, suggesting that analysts have recently become bearish on the company's earnings prospects. Wall Street expects a year-over-year decline in earnings on lower revenues when AbbVie (ABBV) reports results for the quarter ended March 2023. Ho... |
22,627 | 2023-04-19 00:00:00 UTC | Is Merck Stock a Screaming Buy After This $11 Billion Acquisition? | ABBV | https://www.nasdaq.com/articles/is-merck-stock-a-screaming-buy-after-this-%2411-billion-acquisition | null | null | Earlier this week, Merck (NYSE: MRK) went shopping and purchased the precision-medicine company Prometheus Biosciences (NASDAQ: RXDX) for $200 a share, for a total value of $10.8 billion. The transaction is expected to close in the third quarter of 2023.
The deal centers around PRA023, the late-stage autoimmune disorde... | On the con side, Merck will have two entrenched competitors in immunology, AbbVie (NYSE: ABBV) and Johnson & Johnson, along with several other big pharma players in the space. So competing against the likes of AbbVie on its home turf will be a tough ask, to put it mildly. That being said, there's no guarantee that PRA0... | On the con side, Merck will have two entrenched competitors in immunology, AbbVie (NYSE: ABBV) and Johnson & Johnson, along with several other big pharma players in the space. So competing against the likes of AbbVie on its home turf will be a tough ask, to put it mildly. That being said, there's no guarantee that PRA0... | On the con side, Merck will have two entrenched competitors in immunology, AbbVie (NYSE: ABBV) and Johnson & Johnson, along with several other big pharma players in the space. So competing against the likes of AbbVie on its home turf will be a tough ask, to put it mildly. That being said, there's no guarantee that PRA0... | On the con side, Merck will have two entrenched competitors in immunology, AbbVie (NYSE: ABBV) and Johnson & Johnson, along with several other big pharma players in the space. So competing against the likes of AbbVie on its home turf will be a tough ask, to put it mildly. That being said, there's no guarantee that PRA0... |
22,628 | 2023-04-19 00:00:00 UTC | Guru Fundamental Report for ABBV | ABBV | https://www.nasdaq.com/articles/guru-fundamental-report-for-abbv-16 | null | null | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the ... | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the ... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanr... |
22,629 | 2023-04-19 00:00:00 UTC | Noteworthy ETF Inflows: IWB, JPM, CVX, ABBV | ABBV | https://www.nasdaq.com/articles/noteworthy-etf-inflows%3A-iwb-jpm-cvx-abbv | null | null | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Russell 1000 ETF (Symbol: IWB) where we have detected an approximate $216.1 million dollar inflow -- that's a 0.8% increase week over week in outstanding units (from 126,100,000 to 1... | Among the largest underlying components of IWB, in trading today JPMorgan Chase & Co (Symbol: JPM) is down about 0.3%, Chevron Corporation (Symbol: CVX) is off about 0.7%, and AbbVie Inc (Symbol: ABBV) is higher by about 0.5%. These ''units'' can be traded back and forth just like stocks, but can also be created or des... | Among the largest underlying components of IWB, in trading today JPMorgan Chase & Co (Symbol: JPM) is down about 0.3%, Chevron Corporation (Symbol: CVX) is off about 0.7%, and AbbVie Inc (Symbol: ABBV) is higher by about 0.5%. For a complete list of holdings, visit the IWB Holdings page » The chart below shows the one ... | Among the largest underlying components of IWB, in trading today JPMorgan Chase & Co (Symbol: JPM) is down about 0.3%, Chevron Corporation (Symbol: CVX) is off about 0.7%, and AbbVie Inc (Symbol: ABBV) is higher by about 0.5%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered... | Among the largest underlying components of IWB, in trading today JPMorgan Chase & Co (Symbol: JPM) is down about 0.3%, Chevron Corporation (Symbol: CVX) is off about 0.7%, and AbbVie Inc (Symbol: ABBV) is higher by about 0.5%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered... |
22,630 | 2023-04-18 00:00:00 UTC | COWZ ETF: A Cash Cow for Your Portfolio | ABBV | https://www.nasdaq.com/articles/cowz-etf%3A-a-cash-cow-for-your-portfolio | null | null | The market is flooded with plenty of growth ETFs, dividend ETFs, and sector-specific ETFs. How about an ETF that takes an entirely different approach? That’s exactly what the Pacer Cash Cows ETF (BATS:COWZ) does, and it has produced phenomenal annualized total returns of ~31% over the past three years (as of the end of... | In addition to energy, there are quite a few large-cap health and pharma stocks in the top 10, including McKesson (NYSE:MCK), AbbVie (NYSE:ABBV), Gilead (NASDAQ:GILD), and Bristol Myers (NYSE:BMY). That’s exactly what the Pacer Cash Cows ETF (BATS:COWZ) does, and it has produced phenomenal annualized total returns of ~... | In addition to energy, there are quite a few large-cap health and pharma stocks in the top 10, including McKesson (NYSE:MCK), AbbVie (NYSE:ABBV), Gilead (NASDAQ:GILD), and Bristol Myers (NYSE:BMY). The Pacer Cash Cows ETF is a $13.5 billion ETF that invests in the top 100 companies in the Russell 1000 index based on th... | In addition to energy, there are quite a few large-cap health and pharma stocks in the top 10, including McKesson (NYSE:MCK), AbbVie (NYSE:ABBV), Gilead (NASDAQ:GILD), and Bristol Myers (NYSE:BMY). The Pacer Cash Cows ETF is a $13.5 billion ETF that invests in the top 100 companies in the Russell 1000 index based on th... | In addition to energy, there are quite a few large-cap health and pharma stocks in the top 10, including McKesson (NYSE:MCK), AbbVie (NYSE:ABBV), Gilead (NASDAQ:GILD), and Bristol Myers (NYSE:BMY). The Pacer Cash Cows ETF is a $13.5 billion ETF that invests in the top 100 companies in the Russell 1000 index based on th... |
22,631 | 2023-04-18 00:00:00 UTC | AbbVie (ABBV) Stock Sinks As Market Gains: What You Should Know | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-stock-sinks-as-market-gains%3A-what-you-should-know-9 | null | null | AbbVie (ABBV) closed at $159.59 in the latest trading session, marking a -0.99% move from the prior day. This move lagged the S&P 500's daily gain of 0.09%. Elsewhere, the Dow lost 0.03%, while the tech-heavy Nasdaq lost 2.51%.
Coming into today, shares of the drugmaker had gained 3.24% in the past month. In that same ... | AbbVie (ABBV) closed at $159.59 in the latest trading session, marking a -0.99% move from the prior day. Investors will be hoping for strength from AbbVie as it approaches its next earnings release, which is expected to be April 27, 2023. In that report, analysts expect AbbVie to post earnings of $2.47 per share. | AbbVie (ABBV) closed at $159.59 in the latest trading session, marking a -0.99% move from the prior day. Click to get this free report AbbVie Inc. (ABBV) : Free Stock Analysis Report To read this article on Zacks.com click here. Investors will be hoping for strength from AbbVie as it approaches its next earnings releas... | Click to get this free report AbbVie Inc. (ABBV) : Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie (ABBV) closed at $159.59 in the latest trading session, marking a -0.99% move from the prior day. Investors will be hoping for strength from AbbVie as it approaches its next earnings releas... | AbbVie (ABBV) closed at $159.59 in the latest trading session, marking a -0.99% move from the prior day. Investors will be hoping for strength from AbbVie as it approaches its next earnings release, which is expected to be April 27, 2023. In that report, analysts expect AbbVie to post earnings of $2.47 per share. |
22,632 | 2023-04-17 00:00:00 UTC | FDA Approves AbbVie's Qulipta For Preventive Treatment Of Migraine In Adults | ABBV | https://www.nasdaq.com/articles/fda-approves-abbvies-qulipta-for-preventive-treatment-of-migraine-in-adults | null | null | (RTTNews) - AbbVie (ABBV) said that the U.S. Food and Drug Administration approved expanding the indication of Qulipta (atogepant) for the preventive treatment of migraine in adults.
The company noted that the approval makes Qulipta the first and only oral calcitonin gene-related peptide (CGRP) receptor antagonist appr... | (RTTNews) - AbbVie (ABBV) said that the U.S. Food and Drug Administration approved expanding the indication of Qulipta (atogepant) for the preventive treatment of migraine in adults. The company noted that the approval makes Qulipta the first and only oral calcitonin gene-related peptide (CGRP) receptor antagonist appr... | (RTTNews) - AbbVie (ABBV) said that the U.S. Food and Drug Administration approved expanding the indication of Qulipta (atogepant) for the preventive treatment of migraine in adults. The company noted that the approval makes Qulipta the first and only oral calcitonin gene-related peptide (CGRP) receptor antagonist appr... | (RTTNews) - AbbVie (ABBV) said that the U.S. Food and Drug Administration approved expanding the indication of Qulipta (atogepant) for the preventive treatment of migraine in adults. The company noted that the approval makes Qulipta the first and only oral calcitonin gene-related peptide (CGRP) receptor antagonist appr... | (RTTNews) - AbbVie (ABBV) said that the U.S. Food and Drug Administration approved expanding the indication of Qulipta (atogepant) for the preventive treatment of migraine in adults. The company noted that the approval makes Qulipta the first and only oral calcitonin gene-related peptide (CGRP) receptor antagonist appr... |
22,633 | 2023-04-17 00:00:00 UTC | Guru Fundamental Report for ABBV | ABBV | https://www.nasdaq.com/articles/guru-fundamental-report-for-abbv-15 | null | null | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the ... | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the ... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanr... |
22,634 | 2023-04-17 00:00:00 UTC | European Commission Approves AbbVie's Rinvoq To Treat Severely Active Crohn's Disease | ABBV | https://www.nasdaq.com/articles/european-commission-approves-abbvies-rinvoq-to-treat-severely-active-crohns-disease | null | null | (RTTNews) - The European Commission approved Rinvoq (upadacitinib, 45 mg [induction dose] and 15 mg and 30 mg [maintenance doses]) as the first oral Janus Kinase (JAK) inhibitor for the treatment of adult patients with moderately to severely active Crohn's disease who have had an inadequate response, lost response or w... | (RTTNews) - The European Commission approved Rinvoq (upadacitinib, 45 mg [induction dose] and 15 mg and 30 mg [maintenance doses]) as the first oral Janus Kinase (JAK) inhibitor for the treatment of adult patients with moderately to severely active Crohn's disease who have had an inadequate response, lost response or w... | (RTTNews) - The European Commission approved Rinvoq (upadacitinib, 45 mg [induction dose] and 15 mg and 30 mg [maintenance doses]) as the first oral Janus Kinase (JAK) inhibitor for the treatment of adult patients with moderately to severely active Crohn's disease who have had an inadequate response, lost response or w... | (RTTNews) - The European Commission approved Rinvoq (upadacitinib, 45 mg [induction dose] and 15 mg and 30 mg [maintenance doses]) as the first oral Janus Kinase (JAK) inhibitor for the treatment of adult patients with moderately to severely active Crohn's disease who have had an inadequate response, lost response or w... | (RTTNews) - The European Commission approved Rinvoq (upadacitinib, 45 mg [induction dose] and 15 mg and 30 mg [maintenance doses]) as the first oral Janus Kinase (JAK) inhibitor for the treatment of adult patients with moderately to severely active Crohn's disease who have had an inadequate response, lost response or w... |
22,635 | 2023-04-16 00:00:00 UTC | 3 Stocks You Can Keep Forever | ABBV | https://www.nasdaq.com/articles/3-stocks-you-can-keep-forever-8 | null | null | As most investors well know, there is no sure thing in the markets. But promising investments still abound. Three to consider now are AbbVie (NYSE: ABBV), Parker-Hannifin (NYSE: PH), and Carlisle Companies (NYSE: CSL). All three stocks have outpaced the S&P 500 in terms of total return over the past five years and each... | However, AbbVie has been preparing for the Humira patent cliff for a long time and the money the company has put into its huge pipeline should pay off for years to come. Three to consider now are AbbVie (NYSE: ABBV), Parker-Hannifin (NYSE: PH), and Carlisle Companies (NYSE: CSL). While pharmaceutical company AbbVie has... | Three to consider now are AbbVie (NYSE: ABBV), Parker-Hannifin (NYSE: PH), and Carlisle Companies (NYSE: CSL). See the 10 stocks *Stock Advisor returns as of April 10, 2023 Jim Halley has positions in AbbVie, Boeing, Carlisle Companies, and Parker-Hannifin. While pharmaceutical company AbbVie has been heavily reliant o... | Three to consider now are AbbVie (NYSE: ABBV), Parker-Hannifin (NYSE: PH), and Carlisle Companies (NYSE: CSL). While pharmaceutical company AbbVie has been heavily reliant on immuno-oncology drug Humira, it has a huge pipeline of future drugs. ABBV Total Return Level data by YCharts AbbVie: Buy it now and watch it clim... | See the 10 stocks *Stock Advisor returns as of April 10, 2023 Jim Halley has positions in AbbVie, Boeing, Carlisle Companies, and Parker-Hannifin. Three to consider now are AbbVie (NYSE: ABBV), Parker-Hannifin (NYSE: PH), and Carlisle Companies (NYSE: CSL). While pharmaceutical company AbbVie has been heavily reliant o... |
22,636 | 2023-04-16 00:00:00 UTC | 3 Reasons Why I Regret Selling AbbVie | ABBV | https://www.nasdaq.com/articles/3-reasons-why-i-regret-selling-abbvie | null | null | At the end of 2021, I unceremoniously dumped my shares of AbbVie (NYSE: ABBV) stock, which were worth a grand total of around $2,095, marking a total return of 40% on top of what I had initially invested 13 months prior.
While I'm certainly quite glad that I picked up a decent return in a very short period, I admit tod... | At the end of 2021, I unceremoniously dumped my shares of AbbVie (NYSE: ABBV) stock, which were worth a grand total of around $2,095, marking a total return of 40% on top of what I had initially invested 13 months prior. So, here are three reasons why I regret selling AbbVie stock, other than the most obvious reason th... | My reason for selling wasn't well thought out The biggest reason why I regret selling AbbVie is that I didn't sell it for the right reasons. Selling means missing out on dividend income When I sold my shares of AbbVie, my shares were realizing a dividend yield of around 4.5% on my cost basis annually. At the end of 202... | My reason for selling wasn't well thought out The biggest reason why I regret selling AbbVie is that I didn't sell it for the right reasons. I didn't hold my shares long enough to prove or disprove my investing thesis My final regret with selling AbbVie is that in retrospect, I didn't really sell it because my investin... | Selling means missing out on dividend income When I sold my shares of AbbVie, my shares were realizing a dividend yield of around 4.5% on my cost basis annually. I didn't hold my shares long enough to prove or disprove my investing thesis My final regret with selling AbbVie is that in retrospect, I didn't really sell i... |
22,637 | 2023-04-15 00:00:00 UTC | Guru Fundamental Report for ABBV | ABBV | https://www.nasdaq.com/articles/guru-fundamental-report-for-abbv-14 | null | null | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the ... | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the ... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanr... |
22,638 | 2023-04-15 00:00:00 UTC | 3 Dividend Stocks to Buy and Hold for the Next Decade | ABBV | https://www.nasdaq.com/articles/3-dividend-stocks-to-buy-and-hold-for-the-next-decade | null | null | Some stocks are keepers. The best ones even pay you to hold them for years via generous dividends. Three Motley Fool contributors identified their picks for dividend stocks to buy and hold for the next decade. Here's why they chose AbbVie (NYSE: ABBV), Gilead Sciences (NASDAQ: GILD), and Johnson & Johnson (NYSE: JNJ).
... | In addition, the company's pipeline features several promising new programs, with cancer therapy epcoritamab and Parkinson's disease drug ABBV-951 especially standing out. Here's why they chose AbbVie (NYSE: ABBV), Gilead Sciences (NASDAQ: GILD), and Johnson & Johnson (NYSE: JNJ). A temporary storm before the calm Keit... | Here's why they chose AbbVie (NYSE: ABBV), Gilead Sciences (NASDAQ: GILD), and Johnson & Johnson (NYSE: JNJ). A temporary storm before the calm Keith Speights (AbbVie): If you only looked at what AbbVie faces over the near term, you'd likely want to avoid the stock like the plague. However, I view the Humira headwinds ... | Here's why they chose AbbVie (NYSE: ABBV), Gilead Sciences (NASDAQ: GILD), and Johnson & Johnson (NYSE: JNJ). A temporary storm before the calm Keith Speights (AbbVie): If you only looked at what AbbVie faces over the near term, you'd likely want to avoid the stock like the plague. However, I view the Humira headwinds ... | Here's why they chose AbbVie (NYSE: ABBV), Gilead Sciences (NASDAQ: GILD), and Johnson & Johnson (NYSE: JNJ). A temporary storm before the calm Keith Speights (AbbVie): If you only looked at what AbbVie faces over the near term, you'd likely want to avoid the stock like the plague. However, I view the Humira headwinds ... |
22,639 | 2023-04-14 00:00:00 UTC | J&J (JNJ) to Initiate Q1 Earnings Season for Pharma Sector | ABBV | https://www.nasdaq.com/articles/jj-jnj-to-initiate-q1-earnings-season-for-pharma-sector | null | null | Johnson & Johnson JNJ will report first-quarter 2023 results on Apr 18, before market open. In the last reported quarter, the company delivered an earnings surprise of 5.86%.
The healthcare bellwether’s performance has been pretty impressive, with the company exceeding earnings expectations in each of the trailing four... | AbbVie ABBV has an Earnings ESP of +3.21% and a Zacks Rank #3. AbbVie’s stock has risen 0.2% in the past year. AbbVie beat earnings estimates in all the last four quarters. | Click to get this free report Johnson & Johnson (JNJ) : Free Stock Analysis Report Novo Nordisk A/S (NVO) : Free Stock Analysis Report Eli Lilly and Company (LLY) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie ABBV has an Earnings ESP of... | Click to get this free report Johnson & Johnson (JNJ) : Free Stock Analysis Report Novo Nordisk A/S (NVO) : Free Stock Analysis Report Eli Lilly and Company (LLY) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie ABBV has an Earnings ESP of... | AbbVie ABBV has an Earnings ESP of +3.21% and a Zacks Rank #3. AbbVie’s stock has risen 0.2% in the past year. AbbVie beat earnings estimates in all the last four quarters. |
22,640 | 2023-04-14 00:00:00 UTC | Pharma Stock Roundup: FDA Rejects LLY's Mirikizumab, NVO Ups 2023 Sales & Profit View | ABBV | https://www.nasdaq.com/articles/pharma-stock-roundup%3A-fda-rejects-llys-mirikizumab-nvo-ups-2023-sales-profit-view | null | null | This week, Novo Nordisk NVO raised its previously issued sales and operating profit growth guidance for 2023 due to better-than-expected sales performance of its drugs, Wegovy and Ozempic. Eli Lilly LLY and Merck MRK announced pipeline setbacks. AbbVie ABBV voluntarily withdrew accelerated approvals granted for two blo... | AbbVie ABBV voluntarily withdrew accelerated approvals granted for two blood cancer indications for Imbruvica as the confirmatory studies failed to show favorable outcomes. AbbVie Withdraws Two Blood Cancer Indications for Imbruvica: AbbVie announced that it is voluntarily withdrawing the accelerated approval granted ... | AbbVie Withdraws Two Blood Cancer Indications for Imbruvica: AbbVie announced that it is voluntarily withdrawing the accelerated approval granted to its drug Imbruvica for two blood cancer indications in the United States. Click to get this free report Novo Nordisk A/S (NVO) : Free Stock Analysis Report Merck & Co., I... | Click to get this free report Novo Nordisk A/S (NVO) : Free Stock Analysis Report Merck & Co., Inc. (MRK) : Free Stock Analysis Report Eli Lilly and Company (LLY) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie ABBV voluntarily withdrew a... | AbbVie ABBV voluntarily withdrew accelerated approvals granted for two blood cancer indications for Imbruvica as the confirmatory studies failed to show favorable outcomes. AbbVie Withdraws Two Blood Cancer Indications for Imbruvica: AbbVie announced that it is voluntarily withdrawing the accelerated approval granted ... |
22,641 | 2023-04-14 00:00:00 UTC | Here is What to Know Beyond Why AbbVie Inc. (ABBV) is a Trending Stock | ABBV | https://www.nasdaq.com/articles/here-is-what-to-know-beyond-why-abbvie-inc.-abbv-is-a-trending-stock-2 | null | null | AbbVie (ABBV) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.
Shares of this drugmaker have returned +4.8% over the past month versus the Zacks S&P 500 composite's +7.7% chan... | Conclusion The facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about AbbVie. AbbVie (ABBV) has recently been on Zacks.com's list of the most searched stocks. The Zacks Large Cap Pharmaceuticals industry, to which AbbVie... | For the next fiscal year, the consensus earnings estimate of $11.01 indicates a change of +0.5% from what AbbVie is expected to report a year ago. AbbVie (ABBV) has recently been on Zacks.com's list of the most searched stocks. The Zacks Large Cap Pharmaceuticals industry, to which AbbVie belongs, has gained 12.7% over... | Due to the size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, AbbVie is rated Zacks Rank #3 (Hold). AbbVie (ABBV) has recently been on Zacks.com's list of the most searched stocks. The Zacks Large Cap Pharmaceuticals industry, to which AbbVie belongs, has ... | Due to the size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, AbbVie is rated Zacks Rank #3 (Hold). AbbVie (ABBV) has recently been on Zacks.com's list of the most searched stocks. The Zacks Large Cap Pharmaceuticals industry, to which AbbVie belongs, has ... |
22,642 | 2023-04-14 00:00:00 UTC | UnitedHealth ups profit view as lower medical costs drive quarterly beat | ABBV | https://www.nasdaq.com/articles/unitedhealth-ups-profit-view-as-lower-medical-costs-drive-quarterly-beat | null | null | adds details on forecast
April 14 (Reuters) - UnitedHealth Group Inc UNH.Nbeat Wall Street estimates for quarterly profit on Friday and raised its annual forecast, after a slow recovery in non-urgent procedures helped lower medical costs at its insurance unit.
The industry bellwether expects costs from medical claims t... | adds details on forecast April 14 (Reuters) - UnitedHealth Group Inc UNH.Nbeat Wall Street estimates for quarterly profit on Friday and raised its annual forecast, after a slow recovery in non-urgent procedures helped lower medical costs at its insurance unit. The industry bellwether expects costs from medical claims t... | adds details on forecast April 14 (Reuters) - UnitedHealth Group Inc UNH.Nbeat Wall Street estimates for quarterly profit on Friday and raised its annual forecast, after a slow recovery in non-urgent procedures helped lower medical costs at its insurance unit. The industry bellwether expects costs from medical claims t... | adds details on forecast April 14 (Reuters) - UnitedHealth Group Inc UNH.Nbeat Wall Street estimates for quarterly profit on Friday and raised its annual forecast, after a slow recovery in non-urgent procedures helped lower medical costs at its insurance unit. UnitedHealth raised its annual profit forecast to between $... | adds details on forecast April 14 (Reuters) - UnitedHealth Group Inc UNH.Nbeat Wall Street estimates for quarterly profit on Friday and raised its annual forecast, after a slow recovery in non-urgent procedures helped lower medical costs at its insurance unit. The industry bellwether expects costs from medical claims t... |
22,643 | 2023-04-14 00:00:00 UTC | UnitedHealth Group beats quarterly profit estimates on lower medical costs | ABBV | https://www.nasdaq.com/articles/unitedhealth-group-beats-quarterly-profit-estimates-on-lower-medical-costs | null | null | April 14 (Reuters) - UnitedHealth Group Inc's UNH.N quarterly profit beat Wall Street estimates on Friday, as a slow recovery in non-urgent procedures helped lower medical costs at its insurance unit.
Excluding items, the company reported a profit of $6.26 per share for the first quarter, beating analysts' average esti... | April 14 (Reuters) - UnitedHealth Group Inc's UNH.N quarterly profit beat Wall Street estimates on Friday, as a slow recovery in non-urgent procedures helped lower medical costs at its insurance unit. Excluding items, the company reported a profit of $6.26 per share for the first quarter, beating analysts' average esti... | April 14 (Reuters) - UnitedHealth Group Inc's UNH.N quarterly profit beat Wall Street estimates on Friday, as a slow recovery in non-urgent procedures helped lower medical costs at its insurance unit. Excluding items, the company reported a profit of $6.26 per share for the first quarter, beating analysts' average esti... | April 14 (Reuters) - UnitedHealth Group Inc's UNH.N quarterly profit beat Wall Street estimates on Friday, as a slow recovery in non-urgent procedures helped lower medical costs at its insurance unit. Excluding items, the company reported a profit of $6.26 per share for the first quarter, beating analysts' average esti... | April 14 (Reuters) - UnitedHealth Group Inc's UNH.N quarterly profit beat Wall Street estimates on Friday, as a slow recovery in non-urgent procedures helped lower medical costs at its insurance unit. Excluding items, the company reported a profit of $6.26 per share for the first quarter, beating analysts' average esti... |
22,644 | 2023-04-13 00:00:00 UTC | US FDA declines to approve Eli Lilly's bowel disease drug | ABBV | https://www.nasdaq.com/articles/us-fda-declines-to-approve-eli-lillys-bowel-disease-drug | null | null | Adds details
April 13 (Reuters) - The U.S. Food and Drug Administration (FDA) has declined approval for Eli Lilly and Co's LLY.Ndrug to treat a type of chronic inflammatory bowel disease in adults, the company said on Thursday.
The health regulator cited issues related to the proposed manufacturing of the drug, mirikiz... | Adds details April 13 (Reuters) - The U.S. Food and Drug Administration (FDA) has declined approval for Eli Lilly and Co's LLY.Ndrug to treat a type of chronic inflammatory bowel disease in adults, the company said on Thursday. The health regulator cited issues related to the proposed manufacturing of the drug, mirikiz... | Adds details April 13 (Reuters) - The U.S. Food and Drug Administration (FDA) has declined approval for Eli Lilly and Co's LLY.Ndrug to treat a type of chronic inflammatory bowel disease in adults, the company said on Thursday. The company said it was confident in the drug's late-stage data and was working with the FDA... | Adds details April 13 (Reuters) - The U.S. Food and Drug Administration (FDA) has declined approval for Eli Lilly and Co's LLY.Ndrug to treat a type of chronic inflammatory bowel disease in adults, the company said on Thursday. The health regulator cited issues related to the proposed manufacturing of the drug, mirikiz... | Adds details April 13 (Reuters) - The U.S. Food and Drug Administration (FDA) has declined approval for Eli Lilly and Co's LLY.Ndrug to treat a type of chronic inflammatory bowel disease in adults, the company said on Thursday. The health regulator cited issues related to the proposed manufacturing of the drug, mirikiz... |
22,645 | 2023-04-13 00:00:00 UTC | The Zacks Analyst Blog Highlights JPMorgan Chase, AbbVie, NextEra Energy, The Boeing and Canadian Natural Resources | ABBV | https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights-jpmorgan-chase-abbvie-nextera-energy-the-boeing-and | null | null | For Immediate Release
Chicago, IL – April 13, 2023 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: JPMorgan Chase & Co. JPM, Ab... | Stocks recently featured in the blog include: JPMorgan Chase & Co. JPM, AbbVie Inc. ABBV, NextEra Energy, Inc. NEE, The Boeing Co. BA and Canadian Natural Resources Ltd. CNQ. Here are highlights from Wednesday’s Analyst Blog: Top Research Reports for JPMorgan, AbbVie and NextEra Energy The Zacks Research Daily presents... | Stocks recently featured in the blog include: JPMorgan Chase & Co. JPM, AbbVie Inc. ABBV, NextEra Energy, Inc. NEE, The Boeing Co. BA and Canadian Natural Resources Ltd. CNQ. Today's Research Daily features new research reports on 16 major stocks, including JPMorgan Chase & Co., AbbVie Inc. and NextEra Energy, Inc. Cli... | Here are highlights from Wednesday’s Analyst Blog: Top Research Reports for JPMorgan, AbbVie and NextEra Energy The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including JPMorgan Chase & Co., AbbVie Inc. and NextEra... | Today's Research Daily features new research reports on 16 major stocks, including JPMorgan Chase & Co., AbbVie Inc. and NextEra Energy, Inc. Stocks recently featured in the blog include: JPMorgan Chase & Co. JPM, AbbVie Inc. ABBV, NextEra Energy, Inc. NEE, The Boeing Co. BA and Canadian Natural Resources Ltd. CNQ. Her... |
22,646 | 2023-04-12 00:00:00 UTC | Noteworthy Wednesday Option Activity: KMX, AAL, ABBV | ABBV | https://www.nasdaq.com/articles/noteworthy-wednesday-option-activity%3A-kmx-aal-abbv | null | null | Looking at options trading activity among components of the S&P 500 index, there is noteworthy activity today in Carmax Inc. (Symbol: KMX), where a total volume of 41,667 contracts has been traded thus far today, a contract volume which is representative of approximately 4.2 million underlying shares (given that every ... | Especially high volume was seen for the $165 strike call option expiring April 14, 2023, with 23,565 contracts trading so far today, representing approximately 2.4 million underlying shares of ABBV. Below is a chart showing AAL's trailing twelve month trading history, with the $14 strike highlighted in orange: And AbbV... | Below is a chart showing AAL's trailing twelve month trading history, with the $14 strike highlighted in orange: And AbbVie Inc (Symbol: ABBV) options are showing a volume of 35,299 contracts thus far today. That number of contracts represents approximately 3.5 million underlying shares, working out to a sizeable 54% o... | That number of contracts represents approximately 3.5 million underlying shares, working out to a sizeable 54% of ABBV's average daily trading volume over the past month, of 6.5 million shares. Below is a chart showing AAL's trailing twelve month trading history, with the $14 strike highlighted in orange: And AbbVie In... | That number of contracts represents approximately 3.5 million underlying shares, working out to a sizeable 54% of ABBV's average daily trading volume over the past month, of 6.5 million shares. Especially high volume was seen for the $165 strike call option expiring April 14, 2023, with 23,565 contracts trading so far ... |
22,647 | 2023-04-12 00:00:00 UTC | Top Research Reports for JPMorgan Chase, AbbVie & NextEra Energy | ABBV | https://www.nasdaq.com/articles/top-research-reports-for-jpmorgan-chase-abbvie-nextera-energy | null | null | Wednesday, April 12, 2023
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including JPMorgan Chase & Co. (JPM), AbbVie Inc. (ABBV) and NextEra Energy, Inc. (NEE). These research reports have been hand-picked from t... | If you want an email notification each time Sheraz publishes a new article, please click here>>> Today's Must Read Higher Rates, Buyouts Aid JPMorgan (JPM), Fee Income a Woe AbbVie's (ABBV) Skyrizi, Rinvoq Key to Long-Term Growth Steady Investment & Renewable Focus Aid NextEra Energy (NEE) Featured Reports Order Growth... | If you want an email notification each time Sheraz publishes a new article, please click here>>> Today's Must Read Higher Rates, Buyouts Aid JPMorgan (JPM), Fee Income a Woe AbbVie's (ABBV) Skyrizi, Rinvoq Key to Long-Term Growth Steady Investment & Renewable Focus Aid NextEra Energy (NEE) Featured Reports Order Growth... | If you want an email notification each time Sheraz publishes a new article, please click here>>> Today's Must Read Higher Rates, Buyouts Aid JPMorgan (JPM), Fee Income a Woe AbbVie's (ABBV) Skyrizi, Rinvoq Key to Long-Term Growth Steady Investment & Renewable Focus Aid NextEra Energy (NEE) Featured Reports Order Growth... | If you want an email notification each time Sheraz publishes a new article, please click here>>> Today's Must Read Higher Rates, Buyouts Aid JPMorgan (JPM), Fee Income a Woe AbbVie's (ABBV) Skyrizi, Rinvoq Key to Long-Term Growth Steady Investment & Renewable Focus Aid NextEra Energy (NEE) Featured Reports Order Growth... |
22,648 | 2023-04-12 00:00:00 UTC | See Which Of The Latest 13F Filers Holds AbbVie | ABBV | https://www.nasdaq.com/articles/see-which-of-the-latest-13f-filers-holds-abbvie-6 | null | null | At Holdings Channel, we have reviewed the latest batch of the 24 most recent 13F filings for the 03/31/2023 reporting period, and noticed that AbbVie Inc (Symbol: ABBV) was held by 16 of these funds. When hedge fund managers appear to be thinking alike, we find it is a good idea to take a closer look.
Before we proceed... | At Holdings Channel, we have reviewed the latest batch of the 24 most recent 13F filings for the 03/31/2023 reporting period, and noticed that AbbVie Inc (Symbol: ABBV) was held by 16 of these funds. While looking at individual 13F filings can sometimes be misleading due to the long-only nature of the information, the ... | Existing -4,177 -$713 Epiq Partners LLC Existing +40 -$37 Founders Capital Management Existing -372 -$140 626 Financial LLC Existing UNCH -$13 Atlas Private Wealth Advisors Existing +193 +$28 Gulf International Bank UK Ltd Existing -64,000 -$10,859 Naviter Wealth LLC Existing +68 +$86 First National Bank of Mount Dora ... | Existing -4,177 -$713 Epiq Partners LLC Existing +40 -$37 Founders Capital Management Existing -372 -$140 626 Financial LLC Existing UNCH -$13 Atlas Private Wealth Advisors Existing +193 +$28 Gulf International Bank UK Ltd Existing -64,000 -$10,859 Naviter Wealth LLC Existing +68 +$86 First National Bank of Mount Dora ... | Existing -4,177 -$713 Epiq Partners LLC Existing +40 -$37 Founders Capital Management Existing -372 -$140 626 Financial LLC Existing UNCH -$13 Atlas Private Wealth Advisors Existing +193 +$28 Gulf International Bank UK Ltd Existing -64,000 -$10,859 Naviter Wealth LLC Existing +68 +$86 First National Bank of Mount Dora ... |
22,649 | 2023-04-12 00:00:00 UTC | Why AbbVie (ABBV) Could Beat Earnings Estimates Again | ABBV | https://www.nasdaq.com/articles/why-abbvie-abbv-could-beat-earnings-estimates-again | null | null | Have you been searching for a stock that might be well-positioned to maintain its earnings-beat streak in its upcoming report? It is worth considering AbbVie (ABBV), which belongs to the Zacks Large Cap Pharmaceuticals industry.
When looking at the last two reports, this drugmaker has recorded a strong streak of surpas... | It is worth considering AbbVie (ABBV), which belongs to the Zacks Large Cap Pharmaceuticals industry. For the last reported quarter, AbbVie came out with earnings of $3.60 per share versus the Zacks Consensus Estimate of $3.54 per share, representing a surprise of 1.69%. Price and EPS Surprise For AbbVie, estimates hav... | It is worth considering AbbVie (ABBV), which belongs to the Zacks Large Cap Pharmaceuticals industry. For the last reported quarter, AbbVie came out with earnings of $3.60 per share versus the Zacks Consensus Estimate of $3.54 per share, representing a surprise of 1.69%. Price and EPS Surprise For AbbVie, estimates hav... | It is worth considering AbbVie (ABBV), which belongs to the Zacks Large Cap Pharmaceuticals industry. For the last reported quarter, AbbVie came out with earnings of $3.60 per share versus the Zacks Consensus Estimate of $3.54 per share, representing a surprise of 1.69%. Price and EPS Surprise For AbbVie, estimates hav... | It is worth considering AbbVie (ABBV), which belongs to the Zacks Large Cap Pharmaceuticals industry. For the last reported quarter, AbbVie came out with earnings of $3.60 per share versus the Zacks Consensus Estimate of $3.54 per share, representing a surprise of 1.69%. Price and EPS Surprise For AbbVie, estimates hav... |
22,650 | 2023-04-12 00:00:00 UTC | Guru Fundamental Report for ABBV | ABBV | https://www.nasdaq.com/articles/guru-fundamental-report-for-abbv-13 | null | null | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the ... | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the ... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanr... |
22,651 | 2023-04-12 00:00:00 UTC | Why 2023 Could Be a Tough Year for AbbVie Stock | ABBV | https://www.nasdaq.com/articles/why-2023-could-be-a-tough-year-for-abbvie-stock | null | null | At first glance, AbbVie (NYSE: ABBV) might look like a stock that's reasonably valued or even a cheap buy. It even has the added bonus of an attractive dividend yield of 3.7%. But there are some risks under the hood that should give investors some second thoughts about owning this pharmaceutical stock.
Here's why this ... | AbbVie announced multiple acquisitions in 2022, including U.K.-based biotech company DJS Antibodies and Syndesi Therapeutics, which is a Belgian-based business that focuses on cognitive disorders. At first glance, AbbVie (NYSE: ABBV) might look like a stock that's reasonably valued or even a cheap buy. Humira's sales w... | At a forward price-to-earnings multiple of 15 (which is based on analyst expectations), AbbVie's stock is also trading below the healthcare average of 18, and it even leaves a bit of a buffer for investors in case things go worse for the company than expected. At first glance, AbbVie (NYSE: ABBV) might look like a stoc... | Humira's sales will nosedive this year Investors have been hesitant about buying AbbVie stock because its top-selling drug Humira is losing some of its patent protection. At first glance, AbbVie (NYSE: ABBV) might look like a stock that's reasonably valued or even a cheap buy. That reality is hitting hard this year, as... | Humira's sales will nosedive this year Investors have been hesitant about buying AbbVie stock because its top-selling drug Humira is losing some of its patent protection. At first glance, AbbVie (NYSE: ABBV) might look like a stock that's reasonably valued or even a cheap buy. That reality is hitting hard this year, as... |
22,652 | 2023-04-11 00:00:00 UTC | AbbVie (ABBV) Stock Moves 0.06%: What You Should Know | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-stock-moves-0.06%3A-what-you-should-know | null | null | AbbVie (ABBV) closed at $161.38 in the latest trading session, marking a +0.06% move from the prior day. Elsewhere, the Dow gained 0.29%, while the tech-heavy Nasdaq added 1.92%.
Prior to today's trading, shares of the drugmaker had gained 6.14% over the past month. This has lagged the Medical sector's gain of 6.4% and... | AbbVie (ABBV) closed at $161.38 in the latest trading session, marking a +0.06% move from the prior day. AbbVie will be looking to display strength as it nears its next earnings release, which is expected to be April 27, 2023. In that report, analysts expect AbbVie to post earnings of $2.49 per share. | Click to get this free report AbbVie Inc. (ABBV) : Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie (ABBV) closed at $161.38 in the latest trading session, marking a +0.06% move from the prior day. AbbVie will be looking to display strength as it nears its next earnings release, which is ... | Click to get this free report AbbVie Inc. (ABBV) : Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie (ABBV) closed at $161.38 in the latest trading session, marking a +0.06% move from the prior day. AbbVie will be looking to display strength as it nears its next earnings release, which is ... | AbbVie (ABBV) closed at $161.38 in the latest trading session, marking a +0.06% move from the prior day. AbbVie will be looking to display strength as it nears its next earnings release, which is expected to be April 27, 2023. In that report, analysts expect AbbVie to post earnings of $2.49 per share. |
22,653 | 2023-04-11 00:00:00 UTC | Ex-Dividend Reminder: AbbVie, Abbott Laboratories and Mid-America Apartment Communities | ABBV | https://www.nasdaq.com/articles/ex-dividend-reminder%3A-abbvie-abbott-laboratories-and-mid-america-apartment-communities-0 | null | null | Looking at the universe of stocks we cover at Dividend Channel, on 4/13/23, AbbVie Inc (Symbol: ABBV), Abbott Laboratories (Symbol: ABT), and Mid-America Apartment Communities Inc (Symbol: MAA) will all trade ex-dividend for their respective upcoming dividends. AbbVie Inc will pay its quarterly dividend of $1.48 on 5/1... | If they do continue, the current estimated yields on annualized basis would be 3.66% for AbbVie Inc, 1.96% for Abbott Laboratories, and 3.74% for Mid-America Apartment Communities Inc. Looking at the universe of stocks we cover at Dividend Channel, on 4/13/23, AbbVie Inc (Symbol: ABBV), Abbott Laboratories (Symbol: ABT... | Looking at the universe of stocks we cover at Dividend Channel, on 4/13/23, AbbVie Inc (Symbol: ABBV), Abbott Laboratories (Symbol: ABT), and Mid-America Apartment Communities Inc (Symbol: MAA) will all trade ex-dividend for their respective upcoming dividends. AbbVie Inc (Symbol: ABBV): Abbott Laboratories (Symbol: AB... | Looking at the universe of stocks we cover at Dividend Channel, on 4/13/23, AbbVie Inc (Symbol: ABBV), Abbott Laboratories (Symbol: ABT), and Mid-America Apartment Communities Inc (Symbol: MAA) will all trade ex-dividend for their respective upcoming dividends. AbbVie Inc will pay its quarterly dividend of $1.48 on 5/1... | As a percentage of ABBV's recent stock price of $161.65, this dividend works out to approximately 0.92%, so look for shares of AbbVie Inc to trade 0.92% lower — all else being equal — when ABBV shares open for trading on 4/13/23. If they do continue, the current estimated yields on annualized basis would be 3.66% for A... |
22,654 | 2023-04-11 00:00:00 UTC | 2 Forever Stocks to Buy No Matter What the Market Is Doing | ABBV | https://www.nasdaq.com/articles/2-forever-stocks-to-buy-no-matter-what-the-market-is-doing | null | null | In tough economic times, many companies see their revenue decline. And in good times, these companies may see just the opposite -- revenue takes off. It's fine to include these players in your portfolio. But it's also a great idea to buy companies that generally deliver earnings growth no matter what the market is doin... | Pfizer trades for about 12 times forward-earnings estimates, making it cheaper than peers such as Merck or AbbVie. But it's also a great idea to buy companies that generally deliver earnings growth no matter what the market is doing. First, surgical robots are million-dollar investments, so hospitals probably won't aim... | Pfizer trades for about 12 times forward-earnings estimates, making it cheaper than peers such as Merck or AbbVie. Intuitive Surgical Intuitive Surgical (NASDAQ: ISRG) sells and leases robotic surgical systems to hospitals for a wide variety of minimally invasive procedures -- from hernia repair to hysterectomy. Today,... | Pfizer trades for about 12 times forward-earnings estimates, making it cheaper than peers such as Merck or AbbVie. Intuitive Surgical Intuitive Surgical (NASDAQ: ISRG) sells and leases robotic surgical systems to hospitals for a wide variety of minimally invasive procedures -- from hernia repair to hysterectomy. In fac... | Pfizer trades for about 12 times forward-earnings estimates, making it cheaper than peers such as Merck or AbbVie. In tough economic times, many companies see their revenue decline. So, each robot sold or leased results in additional revenue every time a procedure is performed. |
22,655 | 2023-04-10 00:00:00 UTC | Morgan Stanley Maintains AbbVie (ABBV) Overweight Recommendation | ABBV | https://www.nasdaq.com/articles/morgan-stanley-maintains-abbvie-abbv-overweight-recommendation | null | null | Fintel reports that on April 10, 2023, Morgan Stanley maintained coverage of AbbVie (NYSE:ABBV) with a Overweight recommendation.
Analyst Price Forecast Suggests 3.46% Upside
As of April 6, 2023, the average one-year price target for AbbVie is $167.15. The forecasts range from a low of $136.35 to a high of $210.00. The... | Fintel reports that on April 10, 2023, Morgan Stanley maintained coverage of AbbVie (NYSE:ABBV) with a Overweight recommendation. AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. Analyst Price Forecast Suggests 3.46% ... | Fintel reports that on April 10, 2023, Morgan Stanley maintained coverage of AbbVie (NYSE:ABBV) with a Overweight recommendation. Analyst Price Forecast Suggests 3.46% Upside As of April 6, 2023, the average one-year price target for AbbVie is $167.15. The projected annual revenue for AbbVie is $55,229MM, a decrease of... | AbbVie Declares $1.48 Dividend On February 16, 2023 the company declared a regular quarterly dividend of $1.48 per share ($5.92 annualized). Fintel reports that on April 10, 2023, Morgan Stanley maintained coverage of AbbVie (NYSE:ABBV) with a Overweight recommendation. Analyst Price Forecast Suggests 3.46% Upside As o... | Fintel reports that on April 10, 2023, Morgan Stanley maintained coverage of AbbVie (NYSE:ABBV) with a Overweight recommendation. Analyst Price Forecast Suggests 3.46% Upside As of April 6, 2023, the average one-year price target for AbbVie is $167.15. The projected annual revenue for AbbVie is $55,229MM, a decrease of... |
22,656 | 2023-04-10 00:00:00 UTC | AbbVie (ABBV), J&J to Withdraw 2 Blood Cancer Nods for Imbruvica | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-jj-to-withdraw-2-blood-cancer-nods-for-imbruvica | null | null | AbbVie ABBV and Johnson & Johnson JNJ announced they would voluntarily withdraw the accelerated approvals granted by the FDA to Imbruvica (ibrutinib) in mantle cell lymphoma (MCL) and marginal zone lymphoma (MZL) indications. This decision was made in consultation with the FDA.
This decision to voluntarily withdraw two... | AbbVie ABBV and Johnson & Johnson JNJ announced they would voluntarily withdraw the accelerated approvals granted by the FDA to Imbruvica (ibrutinib) in mantle cell lymphoma (MCL) and marginal zone lymphoma (MZL) indications. In the year so far, shares of AbbVie have registered breakeven growth while J&J’s stock price ... | AbbVie Inc. Price AbbVie Inc. price | AbbVie Inc. Quote Johnson & Johnson Price Johnson & Johnson price | Johnson & Johnson Quote Zacks Rank & Stocks to Consider Both AbbVie and J&J currently carry a Zacks Rank #3 (Hold). Click to get this free report AstraZeneca PLC (AZN) : Free Stock Analysis Report Johnson & Johnson... | AbbVie Inc. Price AbbVie Inc. price | AbbVie Inc. Quote Johnson & Johnson Price Johnson & Johnson price | Johnson & Johnson Quote Zacks Rank & Stocks to Consider Both AbbVie and J&J currently carry a Zacks Rank #3 (Hold). Click to get this free report AstraZeneca PLC (AZN) : Free Stock Analysis Report Johnson & Johnson... | AbbVie ABBV and Johnson & Johnson JNJ announced they would voluntarily withdraw the accelerated approvals granted by the FDA to Imbruvica (ibrutinib) in mantle cell lymphoma (MCL) and marginal zone lymphoma (MZL) indications. J&J shares international profits earned from Imbruvica with AbbVie. In the year so far, shares... |
22,657 | 2023-04-10 00:00:00 UTC | Guru Fundamental Report for ABBV | ABBV | https://www.nasdaq.com/articles/guru-fundamental-report-for-abbv-12 | null | null | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the ... | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the ... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanr... |
22,658 | 2023-04-10 00:00:00 UTC | Is Invesco Dynamic Pharmaceuticals ETF (PJP) a Strong ETF Right Now? | ABBV | https://www.nasdaq.com/articles/is-invesco-dynamic-pharmaceuticals-etf-pjp-a-strong-etf-right-now-7 | null | null | The Invesco Dynamic Pharmaceuticals ETF (PJP) made its debut on 06/23/2005, and is a smart beta exchange traded fund that provides broad exposure to the Health Care ETFs category of the market.
What Are Smart Beta ETFs?
The ETF industry has long been dominated by products based on market cap weighted indexes, a strateg... | Looking at individual holdings, Pfizer Inc (PFE) accounts for about 6.84% of total assets, followed by Merck & Co Inc (MRK) and Abbvie Inc (ABBV). Click to get this free report Invesco Dynamic Pharmaceuticals ETF (PJP): ETF Research Reports Pfizer Inc. (PFE) : Free Stock Analysis Report Merck & Co., Inc. (MRK) : Free S... | Click to get this free report Invesco Dynamic Pharmaceuticals ETF (PJP): ETF Research Reports Pfizer Inc. (PFE) : Free Stock Analysis Report Merck & Co., Inc. (MRK) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report iShares U.S. Pharmaceuticals ETF (IHE): ETF Research Reports VanEck Pharmaceut... | Click to get this free report Invesco Dynamic Pharmaceuticals ETF (PJP): ETF Research Reports Pfizer Inc. (PFE) : Free Stock Analysis Report Merck & Co., Inc. (MRK) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report iShares U.S. Pharmaceuticals ETF (IHE): ETF Research Reports VanEck Pharmaceut... | Looking at individual holdings, Pfizer Inc (PFE) accounts for about 6.84% of total assets, followed by Merck & Co Inc (MRK) and Abbvie Inc (ABBV). Click to get this free report Invesco Dynamic Pharmaceuticals ETF (PJP): ETF Research Reports Pfizer Inc. (PFE) : Free Stock Analysis Report Merck & Co., Inc. (MRK) : Free S... |
22,659 | 2023-04-07 00:00:00 UTC | Guru Fundamental Report for ABBV | ABBV | https://www.nasdaq.com/articles/guru-fundamental-report-for-abbv-11 | null | null | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the ... | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the ... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanr... |
22,660 | 2023-04-07 00:00:00 UTC | Is ProShares S&P 500 Dividend Aristocrats ETF (NOBL) a Strong ETF Right Now? | ABBV | https://www.nasdaq.com/articles/is-proshares-sp-500-dividend-aristocrats-etf-nobl-a-strong-etf-right-now-6 | null | null | Making its debut on 10/09/2013, smart beta exchange traded fund ProShares S&P 500 Dividend Aristocrats ETF (NOBL) provides investors broad exposure to the Style Box - Large Cap Value category of the market.
What Are Smart Beta ETFs?
The ETF industry has long been dominated by products based on market cap weighted index... | Click to get this free report ProShares S&P 500 Dividend Aristocrats ETF (NOBL): ETF Research Reports Abbott Laboratories (ABT) : Free Stock Analysis Report Aflac Incorporated (AFL) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report Vanguard Dividend Appreciation ETF (VIG): ETF Research Report... | Click to get this free report ProShares S&P 500 Dividend Aristocrats ETF (NOBL): ETF Research Reports Abbott Laboratories (ABT) : Free Stock Analysis Report Aflac Incorporated (AFL) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report Vanguard Dividend Appreciation ETF (VIG): ETF Research Report... | Click to get this free report ProShares S&P 500 Dividend Aristocrats ETF (NOBL): ETF Research Reports Abbott Laboratories (ABT) : Free Stock Analysis Report Aflac Incorporated (AFL) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report Vanguard Dividend Appreciation ETF (VIG): ETF Research Report... | Click to get this free report ProShares S&P 500 Dividend Aristocrats ETF (NOBL): ETF Research Reports Abbott Laboratories (ABT) : Free Stock Analysis Report Aflac Incorporated (AFL) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report Vanguard Dividend Appreciation ETF (VIG): ETF Research Report... |
22,661 | 2023-04-06 00:00:00 UTC | AbbVie plans to pull US accelerated approvals for some blood cancer treatments | ABBV | https://www.nasdaq.com/articles/abbvie-plans-to-pull-us-accelerated-approvals-for-some-blood-cancer-treatments | null | null | Adds details
April 6 (Reuters) - AbbVie Inc ABBV.N intends to voluntarily withdraw in the U.S. the accelerated approvals of its Imbruvica drug for patients with certain types of blood cancer, the drugmaker said on Thursday.
The company plans to voluntarily withdraw accelerated approvals of Imbruvica for patients with m... | Adds details April 6 (Reuters) - AbbVie Inc ABBV.N intends to voluntarily withdraw in the U.S. the accelerated approvals of its Imbruvica drug for patients with certain types of blood cancer, the drugmaker said on Thursday. A late-stage study in previously untreated MCL met its main goal of progression-free survival, t... | Adds details April 6 (Reuters) - AbbVie Inc ABBV.N intends to voluntarily withdraw in the U.S. the accelerated approvals of its Imbruvica drug for patients with certain types of blood cancer, the drugmaker said on Thursday. The company plans to voluntarily withdraw accelerated approvals of Imbruvica for patients with m... | Adds details April 6 (Reuters) - AbbVie Inc ABBV.N intends to voluntarily withdraw in the U.S. the accelerated approvals of its Imbruvica drug for patients with certain types of blood cancer, the drugmaker said on Thursday. The company plans to voluntarily withdraw accelerated approvals of Imbruvica for patients with m... | Adds details April 6 (Reuters) - AbbVie Inc ABBV.N intends to voluntarily withdraw in the U.S. the accelerated approvals of its Imbruvica drug for patients with certain types of blood cancer, the drugmaker said on Thursday. The company plans to voluntarily withdraw accelerated approvals of Imbruvica for patients with m... |
22,662 | 2023-04-06 00:00:00 UTC | Unusual Put Option Trade in AbbVie (ABBV) Worth $936.31K | ABBV | https://www.nasdaq.com/articles/unusual-put-option-trade-in-abbvie-abbv-worth-%24936.31k | null | null | On April 6, 2023 at 10:53:11 ET an unusually large $936.31K block of Put contracts in AbbVie (ABBV) was sold, with a strike price of $160.00 / share, expiring in 71 days (on June 16, 2023). Fintel tracks all large options trades, and the premium spent on this trade was 2.22 sigmas above the mean, placing it in the 99.2... | On April 6, 2023 at 10:53:11 ET an unusually large $936.31K block of Put contracts in AbbVie (ABBV) was sold, with a strike price of $160.00 / share, expiring in 71 days (on June 16, 2023). AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical ch... | On April 6, 2023 at 10:53:11 ET an unusually large $936.31K block of Put contracts in AbbVie (ABBV) was sold, with a strike price of $160.00 / share, expiring in 71 days (on June 16, 2023). Fintel tracks all large options trades, and the premium spent on this trade was 2.22 sigmas above the mean, placing it in the 99.2... | AbbVie Declares $1.48 Dividend On February 16, 2023 the company declared a regular quarterly dividend of $1.48 per share ($5.92 annualized). On April 6, 2023 at 10:53:11 ET an unusually large $936.31K block of Put contracts in AbbVie (ABBV) was sold, with a strike price of $160.00 / share, expiring in 71 days (on June ... | Analyst Price Forecast Suggests 3.95% Upside As of April 6, 2023, the average one-year price target for AbbVie is $167.15. On April 6, 2023 at 10:53:11 ET an unusually large $936.31K block of Put contracts in AbbVie (ABBV) was sold, with a strike price of $160.00 / share, expiring in 71 days (on June 16, 2023). Fintel ... |
22,663 | 2023-04-06 00:00:00 UTC | AbbVie intends to withdraw accelerated approvals of blood cancer drug | ABBV | https://www.nasdaq.com/articles/abbvie-intends-to-withdraw-accelerated-approvals-of-blood-cancer-drug | null | null | April 6 (Reuters) - AbbVie Inc said on Thursday it intends to voluntarily withdraw in the U.S. the accelerated approvals of its Imbruvica drug for patients with certain types of blood cancer.
The company said other approved indications for the drug in the U.S. are not affected. (Reporting by Sriparna Roy in Bengaluru; ... | April 6 (Reuters) - AbbVie Inc said on Thursday it intends to voluntarily withdraw in the U.S. the accelerated approvals of its Imbruvica drug for patients with certain types of blood cancer. (Reporting by Sriparna Roy in Bengaluru; Editing by Shilpi Majumdar) ((Sriparna.Roy@thomsonreuters.com;)) Keywords: ABBVIE CANCE... | April 6 (Reuters) - AbbVie Inc said on Thursday it intends to voluntarily withdraw in the U.S. the accelerated approvals of its Imbruvica drug for patients with certain types of blood cancer. (Reporting by Sriparna Roy in Bengaluru; Editing by Shilpi Majumdar) ((Sriparna.Roy@thomsonreuters.com;)) Keywords: ABBVIE CANCE... | April 6 (Reuters) - AbbVie Inc said on Thursday it intends to voluntarily withdraw in the U.S. the accelerated approvals of its Imbruvica drug for patients with certain types of blood cancer. (Reporting by Sriparna Roy in Bengaluru; Editing by Shilpi Majumdar) ((Sriparna.Roy@thomsonreuters.com;)) Keywords: ABBVIE CANCE... | April 6 (Reuters) - AbbVie Inc said on Thursday it intends to voluntarily withdraw in the U.S. the accelerated approvals of its Imbruvica drug for patients with certain types of blood cancer. (Reporting by Sriparna Roy in Bengaluru; Editing by Shilpi Majumdar) ((Sriparna.Roy@thomsonreuters.com;)) Keywords: ABBVIE CANCE... |
22,664 | 2023-04-06 00:00:00 UTC | Health Care Sector Update for 04/06/2023: ZIVO, ABBV, PFE, XLV, IBB | ABBV | https://www.nasdaq.com/articles/health-care-sector-update-for-04-06-2023%3A-zivo-abbv-pfe-xlv-ibb | null | null | Health care stocks were advancing premarket Thursday. The Health Care Select Sector SPDR Fund (XLV) was up 0.27% and the iShares Biotechnology ETF (IBB) was recently unchanged.
Zivo Bioscience (ZIVO) was up more than 4% after saying it has received a $1 million unsecured six-month loan from its Chief Executive Officer ... | AbbVie (ABBV) was slightly lower after saying it expects its Q1 per-share adjusted earnings to take a $0.08 hit from acquired in-process research and development and milestones expense of $150 million on a pre-tax basis. The Health Care Select Sector SPDR Fund (XLV) was up 0.27% and the iShares Biotechnology ETF (IBB) ... | AbbVie (ABBV) was slightly lower after saying it expects its Q1 per-share adjusted earnings to take a $0.08 hit from acquired in-process research and development and milestones expense of $150 million on a pre-tax basis. Health care stocks were advancing premarket Thursday. The Health Care Select Sector SPDR Fund (XLV)... | AbbVie (ABBV) was slightly lower after saying it expects its Q1 per-share adjusted earnings to take a $0.08 hit from acquired in-process research and development and milestones expense of $150 million on a pre-tax basis. The Health Care Select Sector SPDR Fund (XLV) was up 0.27% and the iShares Biotechnology ETF (IBB) ... | AbbVie (ABBV) was slightly lower after saying it expects its Q1 per-share adjusted earnings to take a $0.08 hit from acquired in-process research and development and milestones expense of $150 million on a pre-tax basis. Health care stocks were advancing premarket Thursday. Zivo Bioscience (ZIVO) was up more than 4% af... |
22,665 | 2023-04-06 00:00:00 UTC | Johnson & Johnson (JNJ) Soars 4.5%: Is Further Upside Left in the Stock? | ABBV | https://www.nasdaq.com/articles/johnson-johnson-jnj-soars-4.5%3A-is-further-upside-left-in-the-stock | null | null | Johnson & Johnson JNJ shares ended the last trading session 4.5% higher at $165.61. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 2.9% gain over the past four weeks.
Share price rose after management announced that J&J’s sub... | Another stock from the same industry, AbbVie ABBV, closed the last trading session 0.6% higher at $160.80. Over the past month, ABBV has returned 4.5%. AbbVie's consensus EPS estimate for the upcoming report has changed -0.1% over the past month to $2.49. | AbbVie's consensus EPS estimate for the upcoming report has changed -0.1% over the past month to $2.49. Click to get this free report Johnson & Johnson (JNJ) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report To read this article on Zacks.com click here. Another stock from the same industry, A... | Click to get this free report Johnson & Johnson (JNJ) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report To read this article on Zacks.com click here. Another stock from the same industry, AbbVie ABBV, closed the last trading session 0.6% higher at $160.80. Over the past month, ABBV has return... | AbbVie's consensus EPS estimate for the upcoming report has changed -0.1% over the past month to $2.49. Another stock from the same industry, AbbVie ABBV, closed the last trading session 0.6% higher at $160.80. Over the past month, ABBV has returned 4.5%. |
22,666 | 2023-04-05 00:00:00 UTC | Argus Research Downgrades AbbVie (ABBV) | ABBV | https://www.nasdaq.com/articles/argus-research-downgrades-abbvie-abbv | null | null | On April 5, 2023, Argus Research downgraded their outlook for AbbVie (NYSE:ABBV) from Buy to Hold .
Analyst Price Forecast Suggests 4.61% Upside
As of March 30, 2023, the average one-year price target for AbbVie is $167.15. The forecasts range from a low of $136.35 to a high of $210.00. The average price target represe... | AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. On April 5, 2023, Argus Research downgraded their outlook for AbbVie (NYSE:ABBV) from Buy to Hold . Analyst Price Forecast Suggests 4.61% Upside As of March 30, 2023, t... | On April 5, 2023, Argus Research downgraded their outlook for AbbVie (NYSE:ABBV) from Buy to Hold . Analyst Price Forecast Suggests 4.61% Upside As of March 30, 2023, the average one-year price target for AbbVie is $167.15. The projected annual revenue for AbbVie is $55,229MM, a decrease of 4.87%. | AbbVie Declares $1.48 Dividend On February 16, 2023 the company declared a regular quarterly dividend of $1.48 per share ($5.92 annualized). On April 5, 2023, Argus Research downgraded their outlook for AbbVie (NYSE:ABBV) from Buy to Hold . Analyst Price Forecast Suggests 4.61% Upside As of March 30, 2023, the average ... | On April 5, 2023, Argus Research downgraded their outlook for AbbVie (NYSE:ABBV) from Buy to Hold . Analyst Price Forecast Suggests 4.61% Upside As of March 30, 2023, the average one-year price target for AbbVie is $167.15. The projected annual revenue for AbbVie is $55,229MM, a decrease of 4.87%. |
22,667 | 2023-04-05 00:00:00 UTC | Better Dividend Stock: AbbVie vs. Johnson & Johnson | ABBV | https://www.nasdaq.com/articles/better-dividend-stock%3A-abbvie-vs.-johnson-johnson | null | null | The pharmaceutical industry is a great place to look for dividend stocks, and AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ) are among the best. Both drugmakers generally grow their dividends at a good clip, and both are part of the highly exclusive group of Dividend Kings, having raised their payouts for more t... | As a Dividend King, AbbVie has raised its payouts for 51 consecutive years when taking into consideration that it used to be under the banner of medical device giant Abbott Laboratories. AbbVie looks strong enough to overcome the challenges to Humira and come out with a stronger company that still routinely rewards its... | As a Dividend King, AbbVie has raised its payouts for 51 consecutive years when taking into consideration that it used to be under the banner of medical device giant Abbott Laboratories. AbbVie's lower cash payout ratio shows that it can still afford to do so more than Johnson & Johnson, and what's more, AbbVie has a m... | AbbVie's lower cash payout ratio shows that it can still afford to do so more than Johnson & Johnson, and what's more, AbbVie has a more attractive yield. The pharmaceutical industry is a great place to look for dividend stocks, and AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ) are among the best. The case for ... | The pharmaceutical industry is a great place to look for dividend stocks, and AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ) are among the best. The case for AbbVie: It has an answer to the loss of Humira's patent exclusivity AbbVie is going through a bit of a difficult period. But AbbVie's dividend is safe, and... |
22,668 | 2023-04-05 00:00:00 UTC | Guru Fundamental Report for ABBV | ABBV | https://www.nasdaq.com/articles/guru-fundamental-report-for-abbv-10 | null | null | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the ... | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the ... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanr... |
22,669 | 2023-04-05 00:00:00 UTC | Want to Collect Big Dividends Each Month? Buy These 3 Stocks | ABBV | https://www.nasdaq.com/articles/want-to-collect-big-dividends-each-month-buy-these-3-stocks | null | null | Dividend growth investing is a strategy that can help you achieve financial independence -- a state in which your monthly passive income is equal to or greater than your monthly expenses. Building a balanced portfolio with dividend income coming in every month is a surefire way to reach financial independence in the lo... | AbbVie: Fully prepared to build a bright future Unfortunately, illnesses such as cancer and autoimmune conditions (like rheumatoid arthritis and inflammatory bowel diseases) will eventually impact most people at some point in their lives. The good news is that pharmaceutical companies such as AbbVie (NYSE: ABBV) are wo... | AbbVie: Fully prepared to build a bright future Unfortunately, illnesses such as cancer and autoimmune conditions (like rheumatoid arthritis and inflammatory bowel diseases) will eventually impact most people at some point in their lives. The good news is that pharmaceutical companies such as AbbVie (NYSE: ABBV) are wo... | See the 10 stocks *Stock Advisor returns as of March 8, 2023 Kody Kester has positions in AbbVie, Broadcom, and Vici Properties. AbbVie: Fully prepared to build a bright future Unfortunately, illnesses such as cancer and autoimmune conditions (like rheumatoid arthritis and inflammatory bowel diseases) will eventually i... | See the 10 stocks *Stock Advisor returns as of March 8, 2023 Kody Kester has positions in AbbVie, Broadcom, and Vici Properties. AbbVie: Fully prepared to build a bright future Unfortunately, illnesses such as cancer and autoimmune conditions (like rheumatoid arthritis and inflammatory bowel diseases) will eventually i... |
22,670 | 2023-04-03 00:00:00 UTC | 3 Dividend ETFs to Consider Buying with Your Tax Return | ABBV | https://www.nasdaq.com/articles/3-dividend-etfs-to-consider-buying-with-your-tax-return | null | null | If you’re getting a tax return, there are plenty of ways you can spend it. However, investing in a dividend ETF may be one of the best choices. The top dividend ETFs give you instant diversification to a broad swath of dividend-paying stocks, they pay you passive income on a periodic basis, and you can use these paymen... | JEPI invests in blue-chip U.S. dividend companies like Coca-Cola (NYSE:KO), Pepsi (NASDAQ:PEP), and AbbVie (NYSE:ABBV) and then invests up to 20% of its assets into equity-linked notes or ELNs. Looking at SCHD's top holdings, there are actually quite a few of the same names that you’ll find in JEPI’s fund as well, such... | JEPI invests in blue-chip U.S. dividend companies like Coca-Cola (NYSE:KO), Pepsi (NASDAQ:PEP), and AbbVie (NYSE:ABBV) and then invests up to 20% of its assets into equity-linked notes or ELNs. Looking at SCHD's top holdings, there are actually quite a few of the same names that you’ll find in JEPI’s fund as well, such... | JEPI invests in blue-chip U.S. dividend companies like Coca-Cola (NYSE:KO), Pepsi (NASDAQ:PEP), and AbbVie (NYSE:ABBV) and then invests up to 20% of its assets into equity-linked notes or ELNs. Looking at SCHD's top holdings, there are actually quite a few of the same names that you’ll find in JEPI’s fund as well, such... | JEPI invests in blue-chip U.S. dividend companies like Coca-Cola (NYSE:KO), Pepsi (NASDAQ:PEP), and AbbVie (NYSE:ABBV) and then invests up to 20% of its assets into equity-linked notes or ELNs. Looking at SCHD's top holdings, there are actually quite a few of the same names that you’ll find in JEPI’s fund as well, such... |
22,671 | 2023-04-03 00:00:00 UTC | Guru Fundamental Report for ABBV | ABBV | https://www.nasdaq.com/articles/guru-fundamental-report-for-abbv-9 | null | null | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the ... | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the ... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanr... |
22,672 | 2023-04-03 00:00:00 UTC | AbbVie (ABBV) Outpaces Stock Market Gains: What You Should Know | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-outpaces-stock-market-gains%3A-what-you-should-know-3 | null | null | In the latest trading session, AbbVie (ABBV) closed at $160.42, marking a +0.66% move from the previous day. This move outpaced the S&P 500's daily gain of 0.37%. Elsewhere, the Dow gained 0.98%, while the tech-heavy Nasdaq added 0.62%.
Coming into today, shares of the drugmaker had gained 2.12% in the past month. In t... | In the latest trading session, AbbVie (ABBV) closed at $160.42, marking a +0.66% move from the previous day. Wall Street will be looking for positivity from AbbVie as it approaches its next earnings report date. In that report, analysts expect AbbVie to post earnings of $3.54 per share. | In the latest trading session, AbbVie (ABBV) closed at $160.42, marking a +0.66% move from the previous day. Wall Street will be looking for positivity from AbbVie as it approaches its next earnings report date. In that report, analysts expect AbbVie to post earnings of $3.54 per share. | Click to get this free report AbbVie Inc. (ABBV) : Free Stock Analysis Report To read this article on Zacks.com click here. In the latest trading session, AbbVie (ABBV) closed at $160.42, marking a +0.66% move from the previous day. Wall Street will be looking for positivity from AbbVie as it approaches its next earnin... | In the latest trading session, AbbVie (ABBV) closed at $160.42, marking a +0.66% move from the previous day. Wall Street will be looking for positivity from AbbVie as it approaches its next earnings report date. In that report, analysts expect AbbVie to post earnings of $3.54 per share. |
22,673 | 2023-04-02 00:00:00 UTC | These 5 High-Yield Dividend Stocks Should Make Me $3,000 in Passive Income This Year | ABBV | https://www.nasdaq.com/articles/these-5-high-yield-dividend-stocks-should-make-me-%243000-in-passive-income-this-year | null | null | Nearly everyone has to work for their money. But too few put their money to work for them. There are plenty of ways to do it. My favorite method is investing in stocks.
Stocks can make you money in a couple of key ways. Their share prices can appreciate. Some also pay dividends. My portfolio currently includes 12 high-... | See the 10 stocks *Stock Advisor returns as of March 8, 2023 Keith Speights has positions in AbbVie, Brookfield Infrastructure, Brookfield Infrastructure Partners, Devon Energy, Enterprise Products Partners, and Medical Properties Trust. AbbVie (NYSE: ABBV) 3.73% 9.75% Brookfield Infrastructure (NYSE: BIP) (NYSE: BIPC)... | AbbVie (NYSE: ABBV) 3.73% 9.75% Brookfield Infrastructure (NYSE: BIP) (NYSE: BIPC) 4.55% 4.74% Devon Energy (NYSE: DVN) 10% 11.93% Enterprise Products Partners (NYSE: EPD) 7.56% 8.37% Medical Properties Trust (NYSE: MPW) 14.22% 11.11% Data source for current dividend yields: Google Finance. See the 10 stocks *Stock Adv... | AbbVie (NYSE: ABBV) 3.73% 9.75% Brookfield Infrastructure (NYSE: BIP) (NYSE: BIPC) 4.55% 4.74% Devon Energy (NYSE: DVN) 10% 11.93% Enterprise Products Partners (NYSE: EPD) 7.56% 8.37% Medical Properties Trust (NYSE: MPW) 14.22% 11.11% Data source for current dividend yields: Google Finance. See the 10 stocks *Stock Adv... | What I like about these stocks I initially bought shares of AbbVie because its valuation was attractive. See the 10 stocks *Stock Advisor returns as of March 8, 2023 Keith Speights has positions in AbbVie, Brookfield Infrastructure, Brookfield Infrastructure Partners, Devon Energy, Enterprise Products Partners, and Med... |
22,674 | 2023-04-01 00:00:00 UTC | Could This Drug News Lift AbbVie's Stock? | ABBV | https://www.nasdaq.com/articles/could-this-drug-news-lift-abbvies-stock | null | null | Perhaps as much as any industry, pharmaceutical makers must innovate to survive and thrive. That's because the same patents which protect a medicine from biosimilar competition eventually expire, often leading to a precipitous decline in sales.
Consider AbbVie's (NYSE: ABBV) crown jewel drug, Humira, which hauled in $2... | AbbVie recently enrolled patients in a phase 3 clinical trial for treating moderate to severe cases of systemic lupus erythematosus (SLE), an autoimmune disease. With the company aggressively expanding its indications for Rinvoq and Skyrizi, AbbVie expects that the two drugs will bring in $27 billion in combined annual... | AbbVie recently enrolled patients in a phase 3 clinical trial for treating moderate to severe cases of systemic lupus erythematosus (SLE), an autoimmune disease. Pleased with the results from its phase 2 clinical trials, AbbVie announced just days ago that it had advanced the drug to phase 3 clinical trials. Consider A... | AbbVie recently enrolled patients in a phase 3 clinical trial for treating moderate to severe cases of systemic lupus erythematosus (SLE), an autoimmune disease. Pleased with the results from its phase 2 clinical trials, AbbVie announced just days ago that it had advanced the drug to phase 3 clinical trials. With the c... | AbbVie recently enrolled patients in a phase 3 clinical trial for treating moderate to severe cases of systemic lupus erythematosus (SLE), an autoimmune disease. For the sake of its clinical trial, AbbVie defined SRI-4 as an at least 4-point reduction on the SLE Disease Activity Index 2000 (SLEDAI-2K) score without wor... |
22,675 | 2023-03-31 00:00:00 UTC | This Blockbuster Drug's Latest News Could Be Another Home Run for AbbVie | ABBV | https://www.nasdaq.com/articles/this-blockbuster-drugs-latest-news-could-be-another-home-run-for-abbvie | null | null | AbbVie (NYSE: ABBV) recently shared positive top-line results from its phase 3 clinical trial of Skyrizi that treated patients with moderately to severely active ulcerative colitis (UC).
With an approval from the U.S. Food and Drug Administration looking more like a matter of "when" than "if," it's worth asking the fol... | AbbVie (NYSE: ABBV) recently shared positive top-line results from its phase 3 clinical trial of Skyrizi that treated patients with moderately to severely active ulcerative colitis (UC). AbbVie enrolled patients with moderately to severely active UC in a randomized and double-blind phase 3 clinical trial. But how much ... | AbbVie (NYSE: ABBV) recently shared positive top-line results from its phase 3 clinical trial of Skyrizi that treated patients with moderately to severely active ulcerative colitis (UC). AbbVie enrolled patients with moderately to severely active UC in a randomized and double-blind phase 3 clinical trial. But how much ... | AbbVie (NYSE: ABBV) recently shared positive top-line results from its phase 3 clinical trial of Skyrizi that treated patients with moderately to severely active ulcerative colitis (UC). AbbVie enrolled patients with moderately to severely active UC in a randomized and double-blind phase 3 clinical trial. But how much ... | AbbVie (NYSE: ABBV) recently shared positive top-line results from its phase 3 clinical trial of Skyrizi that treated patients with moderately to severely active ulcerative colitis (UC). AbbVie enrolled patients with moderately to severely active UC in a randomized and double-blind phase 3 clinical trial. But how much ... |
22,676 | 2023-03-31 00:00:00 UTC | The Top Healthcare Stocks to Buy With $100 | ABBV | https://www.nasdaq.com/articles/the-top-healthcare-stocks-to-buy-with-%24100-2 | null | null | A common misconception is that you need a lot of money to invest in the stock market. However, even a small amount is enough to start. With the right stocks, a small investment can grow greatly in value. Some growth stocks have the potential to deliver massive returns as long as you have a little patience and a reasona... | AbbVie Investors became cautious about AbbVie's (NYSE: ABBV) stock after its star drug Humira lost patent exclusivity in the U.S. at the beginning of 2023. In 2022, it generated $21 billion in sales, accounting for 36% of AbbVie's total revenue. However, AbbVie is wise to not rely on a single product to thrive. | AbbVie Investors became cautious about AbbVie's (NYSE: ABBV) stock after its star drug Humira lost patent exclusivity in the U.S. at the beginning of 2023. In 2022, it generated $21 billion in sales, accounting for 36% of AbbVie's total revenue. However, AbbVie is wise to not rely on a single product to thrive. | AbbVie Investors became cautious about AbbVie's (NYSE: ABBV) stock after its star drug Humira lost patent exclusivity in the U.S. at the beginning of 2023. In 2022, it generated $21 billion in sales, accounting for 36% of AbbVie's total revenue. However, AbbVie is wise to not rely on a single product to thrive. | AbbVie Investors became cautious about AbbVie's (NYSE: ABBV) stock after its star drug Humira lost patent exclusivity in the U.S. at the beginning of 2023. In 2022, it generated $21 billion in sales, accounting for 36% of AbbVie's total revenue. However, AbbVie is wise to not rely on a single product to thrive. |
22,677 | 2023-03-31 00:00:00 UTC | Guru Fundamental Report for ABBV | ABBV | https://www.nasdaq.com/articles/guru-fundamental-report-for-abbv-8 | null | null | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the ... | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the ... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanr... |
22,678 | 2023-03-30 00:00:00 UTC | PFE vs. ABBV: Which Pharmaceutical Stock is Better? | ABBV | https://www.nasdaq.com/articles/pfe-vs.-abbv%3A-which-pharmaceutical-stock-is-better | null | null | In this piece, I used TipRanks' comparison tool to evaluate two pharmaceutical stocks, Pfizer Inc. (NYSE:PFE) and AbbVie Inc. (NYSE:ABBV), to determine which is better. Pfizer has plummeted more than 20% year-to-date, while AbbVie has held up much better, with a decline of about 2%. A closer look at both companies reve... | In this piece, I used TipRanks' comparison tool to evaluate two pharmaceutical stocks, Pfizer Inc. (NYSE:PFE) and AbbVie Inc. (NYSE:ABBV), to determine which is better. Pfizer has plummeted more than 20% year-to-date, while AbbVie has held up much better, with a decline of about 2%. A closer look at both companies reve... | At $163.23, the average AbbVie stock price target implies upside potential of 3.36%. Conclusion: Long-Term Bullish on PFE, Neutral on ABBV Pfizer and AbbVie both face significant challenges from patent expirations by the end of the decade, but Pfizer's recent sell-off makes it look like the better choice. In this piece... | AbbVie (NYSE:ABBV) At about 23.8 times earnings, AbbVie is trading slightly above its industry's current P/E, although it's slightly below the mean of 25 times over the last five years. AbbVie expects Humira sales to plummet between 35% and 55% this year, so it faces similar risks as Pfizer, except its shares haven't s... | AbbVie expects Humira sales to plummet between 35% and 55% this year, so it faces similar risks as Pfizer, except its shares haven't sold off like Pfizer's have. Similarly, AbbVie may sell off to the point where it also looks attractive, but we aren't there yet. In this piece, I used TipRanks' comparison tool to evalua... |
22,679 | 2023-03-30 00:00:00 UTC | IVW, CVX, ABBV, MRK: Large Inflows Detected at ETF | ABBV | https://www.nasdaq.com/articles/ivw-cvx-abbv-mrk%3A-large-inflows-detected-at-etf | null | null | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares S&P 500 Growth ETF (Symbol: IVW) where we have detected an approximate $172.1 million dollar inflow -- that's a 0.6% increase week over week in outstanding units (from 466,150,000 to... | Among the largest underlying components of IVW, in trading today Chevron Corporation (Symbol: CVX) is up about 0.7%, AbbVie Inc (Symbol: ABBV) is trading flat, and Merck & Co Inc (Symbol: MRK) is lower by about 0.1%. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to ... | Among the largest underlying components of IVW, in trading today Chevron Corporation (Symbol: CVX) is up about 0.7%, AbbVie Inc (Symbol: ABBV) is trading flat, and Merck & Co Inc (Symbol: MRK) is lower by about 0.1%. For a complete list of holdings, visit the IVW Holdings page » The chart below shows the one year price... | Among the largest underlying components of IVW, in trading today Chevron Corporation (Symbol: CVX) is up about 0.7%, AbbVie Inc (Symbol: ABBV) is trading flat, and Merck & Co Inc (Symbol: MRK) is lower by about 0.1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Ch... | Among the largest underlying components of IVW, in trading today Chevron Corporation (Symbol: CVX) is up about 0.7%, AbbVie Inc (Symbol: ABBV) is trading flat, and Merck & Co Inc (Symbol: MRK) is lower by about 0.1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Ch... |
22,680 | 2023-03-30 00:00:00 UTC | 2 High-Yielding Dividend Investments to Buy for the Long Haul | ABBV | https://www.nasdaq.com/articles/2-high-yielding-dividend-investments-to-buy-for-the-long-haul | null | null | Want some safe stocks you can hold in your portfolio and not worry about, and that also provide high yields? Two companies which fit the bill and you should consider loading up on now are AbbVie (NYSE: ABBV) and Coca-Cola (NYSE: KO). These are among the best dividend stocks you can buy for the long haul.
1. Coca-Cola
O... | AbbVie has a plan to replace that revenue, plus it has some terrific growth prospects ahead, which make both its business and dividend look incredibly strong right now. Two companies which fit the bill and you should consider loading up on now are AbbVie (NYSE: ABBV) and Coca-Cola (NYSE: KO). AbbVie Another Dividend Ki... | Two companies which fit the bill and you should consider loading up on now are AbbVie (NYSE: ABBV) and Coca-Cola (NYSE: KO). While Coca-Cola is benefiting from higher prices, AbbVie may generate a better return for investors due to its growth opportunities. AbbVie Another Dividend King stock is AbbVie. | AbbVie Another Dividend King stock is AbbVie. AbbVie is more of a typical growth stock than Coca-Cola. Two companies which fit the bill and you should consider loading up on now are AbbVie (NYSE: ABBV) and Coca-Cola (NYSE: KO). | AbbVie Another Dividend King stock is AbbVie. AbbVie is more of a typical growth stock than Coca-Cola. Two companies which fit the bill and you should consider loading up on now are AbbVie (NYSE: ABBV) and Coca-Cola (NYSE: KO). |
22,681 | 2023-03-29 00:00:00 UTC | Investing Your Tax Return? Check Out This 11.8%-Yielding ETF | ABBV | https://www.nasdaq.com/articles/investing-your-tax-return-check-out-this-11.8-yielding-etf | null | null | Tax season is upon us once again. If you are getting a tax return, why not consider investing in a dividend ETF instead of spending it on a new gadget or a night out on the town?
Using your tax return to buy a high-yielding dividend ETF can help you to jump-start your own dividend portfolio. Investing in a dividend ETF... | Abbvie (NYSE:ABBV) and UnitedHealth (NYSE:UNH) represent the healthcare sector within the top 10, and payment networks Visa (NYSE:V) and Mastercard (NYSE:MA) also find a home within JEPI. TipRanks uses proprietary technology to compile analyst forecasts and price targets for ETFs based on a combination of the individua... | Abbvie (NYSE:ABBV) and UnitedHealth (NYSE:UNH) represent the healthcare sector within the top 10, and payment networks Visa (NYSE:V) and Mastercard (NYSE:MA) also find a home within JEPI. The ETF “generates income through a combination of selling options and investing in U.S. large-cap stocks, seeking to deliver a mont... | Abbvie (NYSE:ABBV) and UnitedHealth (NYSE:UNH) represent the healthcare sector within the top 10, and payment networks Visa (NYSE:V) and Mastercard (NYSE:MA) also find a home within JEPI. Investing in a dividend ETF like the JPMorgan Equity Premium Income ETF (NYSEARCA:JEPI) gives you access to a diverse array of divid... | Abbvie (NYSE:ABBV) and UnitedHealth (NYSE:UNH) represent the healthcare sector within the top 10, and payment networks Visa (NYSE:V) and Mastercard (NYSE:MA) also find a home within JEPI. Using your tax return to buy a high-yielding dividend ETF can help you to jump-start your own dividend portfolio. The ETF “generates... |
22,682 | 2023-03-29 00:00:00 UTC | Better Growth Stock: Vertex Pharmaceuticals vs. AbbVie | ABBV | https://www.nasdaq.com/articles/better-growth-stock%3A-vertex-pharmaceuticals-vs.-abbvie | null | null | Vertex Pharmaceuticals (NASDAQ: VRTX) and AbbVie (NYSE: ABBV) both beat last year's bear market. In fact, in 2022 these dynamic biotech stocks climbed by percentages in the double digits, and for good reason. People need medicines no matter what the market is doing -- and this helps healthcare companies maintain earnin... | So while this year probably won't be a big one of growth for AbbVie, that should quickly change as Rinvoq and Skyrizi gain regulatory approvals for additional indications. Vertex Pharmaceuticals (NASDAQ: VRTX) and AbbVie (NYSE: ABBV) both beat last year's bear market. Vertex and AbbVie also happen to offer a lot of gro... | So while this year probably won't be a big one of growth for AbbVie, that should quickly change as Rinvoq and Skyrizi gain regulatory approvals for additional indications. All of this means that AbbVie offers solid long-term earnings growth prospects -- and passive income while you wait. Vertex Pharmaceuticals (NASDAQ:... | Vertex Pharmaceuticals (NASDAQ: VRTX) and AbbVie (NYSE: ABBV) both beat last year's bear market. Vertex and AbbVie also happen to offer a lot of growth potential. And AbbVie may become the leader in prescription-drug market share within the next few years. | Vertex or AbbVie? Vertex Pharmaceuticals (NASDAQ: VRTX) and AbbVie (NYSE: ABBV) both beat last year's bear market. Vertex and AbbVie also happen to offer a lot of growth potential. |
22,683 | 2023-03-29 00:00:00 UTC | Guru Fundamental Report for ABBV | ABBV | https://www.nasdaq.com/articles/guru-fundamental-report-for-abbv-7 | null | null | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the ... | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the ... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanr... |
22,684 | 2023-03-29 00:00:00 UTC | Better Growth Stock: AbbVie vs. Pfizer | ABBV | https://www.nasdaq.com/articles/better-growth-stock%3A-abbvie-vs.-pfizer | null | null | AbbVie (NYSE: ABBV) and Pfizer (NYSE: PFE) are two of the world's biggest pharmaceutical companies, and the similarities don't end there. Both players are going to face some headwinds over the next couple of years as the income from their cash cow medicines sharply erodes. Beyond that, however, both have big plans to k... | While that might not seem like rapid growth, it's important to note that AbbVie also pays a dividend that currently has a forward yield of around 3.8%, and it plans to continue doing share repurchases, so investors will get rewarded in more ways than just top-line expansion. It's a close call Both AbbVie and Pfizer are... | For 2022, Humira, its arthritis drug and one of the best-selling medicines of all time, brought in $21.2 billion out of AbbVie's top line of roughly $58 billion. AbbVie (NYSE: ABBV) and Pfizer (NYSE: PFE) are two of the world's biggest pharmaceutical companies, and the similarities don't end there. AbbVie's pivot is pr... | AbbVie's pivot is proceeding as planned The case for AbbVie as a growth stock can't avoid two issues: the decline of Humira, and the stagnation of its oncology portfolio. For 2022, Humira, its arthritis drug and one of the best-selling medicines of all time, brought in $21.2 billion out of AbbVie's top line of roughly ... | For 2022, Humira, its arthritis drug and one of the best-selling medicines of all time, brought in $21.2 billion out of AbbVie's top line of roughly $58 billion. But AbbVie's growth trajectory through 2030 makes it a better growth stock today. Even losing its biggest moneymaker isn't going to cause its top line to sag ... |
22,685 | 2023-03-28 00:00:00 UTC | DIV ETF Yields 7.3% and Pays Monthly. Here are the Pros and Cons | ABBV | https://www.nasdaq.com/articles/div-etf-yields-7.3-and-pays-monthly.-here-are-the-pros-and-cons | null | null | With a monthly dividend payout and a yield that beats inflation, the Global X SuperDividend ETF (NYSEARCA:DIV) is a tempting choice for dividend investors. However, there are several pros and cons that investors should weigh when it comes to this high-yield ETF.
What Does the DIV ETF Do?
DIV is another one of Global ... | DIV's holdings also include a few other well-known U.S. large-cap stocks like Verizon (NYSE:VZ), 3M (NYSE:MMM), and AbbVie (NYSE:ABBV), and then beyond these names, there are plenty of REITs and shipping companies. For instance, Iron Mountain (NYSE:IRM) and Magellan Midstream Partners receive coveted 'Perfect 10' score... | DIV's holdings also include a few other well-known U.S. large-cap stocks like Verizon (NYSE:VZ), 3M (NYSE:MMM), and AbbVie (NYSE:ABBV), and then beyond these names, there are plenty of REITs and shipping companies. For instance, Iron Mountain (NYSE:IRM) and Magellan Midstream Partners receive coveted 'Perfect 10' score... | DIV's holdings also include a few other well-known U.S. large-cap stocks like Verizon (NYSE:VZ), 3M (NYSE:MMM), and AbbVie (NYSE:ABBV), and then beyond these names, there are plenty of REITs and shipping companies. For instance, Iron Mountain (NYSE:IRM) and Magellan Midstream Partners receive coveted 'Perfect 10' score... | DIV's holdings also include a few other well-known U.S. large-cap stocks like Verizon (NYSE:VZ), 3M (NYSE:MMM), and AbbVie (NYSE:ABBV), and then beyond these names, there are plenty of REITs and shipping companies. For instance, Iron Mountain (NYSE:IRM) and Magellan Midstream Partners receive coveted 'Perfect 10' score... |
22,686 | 2023-03-28 00:00:00 UTC | ABBV December 2025 Options Begin Trading | ABBV | https://www.nasdaq.com/articles/abbv-december-2025-options-begin-trading | null | null | Investors in AbbVie Inc (Symbol: ABBV) saw new options begin trading today, for the December 2025 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 997 days until expiration the newly trading contracts represent a possible opportunity for selle... | Of course, a lot of upside could potentially be left on the table if ABBV shares really soar, which is why looking at the trailing twelve month trading history for AbbVie Inc, as well as studying the business fundamentals becomes important. Below is a chart showing ABBV's trailing twelve month trading history, with the... | Below is a chart showing ABBV's trailing twelve month trading history, with the $160.00 strike highlighted in red: Considering the fact that the $160.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the pos... | Below is a chart showing the trailing twelve month trading history for AbbVie Inc, and highlighting in green where the $155.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $160.00 strike price has a current bid of $21.40. Below is a chart showing AB... | At Stock Options Channel, our YieldBoost formula has looked up and down the ABBV options chain for the new December 2025 contracts and identified one put and one call contract of particular interest. Below is a chart showing ABBV's trailing twelve month trading history, with the $160.00 strike highlighted in red: Consi... |
22,687 | 2023-03-28 00:00:00 UTC | 2 Relatively Safe Dividend Stocks You Won't Regret Owning | ABBV | https://www.nasdaq.com/articles/2-relatively-safe-dividend-stocks-you-wont-regret-owning | null | null | Most of us spend a lot of mental energy on trying to avoid bumbling into fresh regrets, especially when it comes to our investments. While there's no ironclad method for picking perfectly safe stocks, thankfully there are a few dividend-paying companies that are a bit less risky than average -- as a result of their his... | AbbVie When it comes to appealing biopharma dividend stocks that investors can depend on, AbbVie (NYSE: ABBV) is near the top of the list. For 2022, AbbVie's net income was over $11.8 billion, and it only paid out around $10 billion in dividends. To accomplish that, AbbVie will be ramping up sales of its latest immunol... | AbbVie When it comes to appealing biopharma dividend stocks that investors can depend on, AbbVie (NYSE: ABBV) is near the top of the list. For 2022, AbbVie's net income was over $11.8 billion, and it only paid out around $10 billion in dividends. To accomplish that, AbbVie will be ramping up sales of its latest immunol... | AbbVie When it comes to appealing biopharma dividend stocks that investors can depend on, AbbVie (NYSE: ABBV) is near the top of the list. For 2022, AbbVie's net income was over $11.8 billion, and it only paid out around $10 billion in dividends. To accomplish that, AbbVie will be ramping up sales of its latest immunol... | AbbVie When it comes to appealing biopharma dividend stocks that investors can depend on, AbbVie (NYSE: ABBV) is near the top of the list. For 2022, AbbVie's net income was over $11.8 billion, and it only paid out around $10 billion in dividends. To accomplish that, AbbVie will be ramping up sales of its latest immunol... |
22,688 | 2023-03-28 00:00:00 UTC | This Is the Best Dividend ETF You Can Buy | ABBV | https://www.nasdaq.com/articles/this-is-the-best-dividend-etf-you-can-buy | null | null | The Schwab U.S. Dividend ETF (NYSEMKT: SCHD) just went through its annual reconstitution, meaning the top positions look different than they did just a few weeks prior. AbbVie (NYSE: ABBV) is now the fund's largest weighted position. SCHD is great because it can offer a solid yield, strong dividend growth, and share ap... | AbbVie (NYSE: ABBV) is now the fund's largest weighted position. See the 10 stocks *Stock Advisor returns as of March 8, 2023 Mark Roussin, CPA has positions in AbbVie and Schwab Strategic Trust-Schwab U.S. Dividend Equity ETF. The Schwab U.S. Dividend ETF (NYSEMKT: SCHD) just went through its annual reconstitution, me... | See the 10 stocks *Stock Advisor returns as of March 8, 2023 Mark Roussin, CPA has positions in AbbVie and Schwab Strategic Trust-Schwab U.S. Dividend Equity ETF. AbbVie (NYSE: ABBV) is now the fund's largest weighted position. 10 stocks we like better than Schwab Strategic Trust-Schwab U.S. Dividend Equity ETF When ou... | See the 10 stocks *Stock Advisor returns as of March 8, 2023 Mark Roussin, CPA has positions in AbbVie and Schwab Strategic Trust-Schwab U.S. Dividend Equity ETF. AbbVie (NYSE: ABBV) is now the fund's largest weighted position. 10 stocks we like better than Schwab Strategic Trust-Schwab U.S. Dividend Equity ETF When ou... | See the 10 stocks *Stock Advisor returns as of March 8, 2023 Mark Roussin, CPA has positions in AbbVie and Schwab Strategic Trust-Schwab U.S. Dividend Equity ETF. AbbVie (NYSE: ABBV) is now the fund's largest weighted position. The Motley Fool has no position in any of the stocks mentioned. |
22,689 | 2023-03-27 00:00:00 UTC | AbbVie (ABBV) Stock Sinks As Market Gains: What You Should Know | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-stock-sinks-as-market-gains%3A-what-you-should-know-8 | null | null | In the latest trading session, AbbVie (ABBV) closed at $157.54, marking a -0.3% move from the previous day. This change lagged the S&P 500's daily gain of 0.17%. Elsewhere, the Dow gained 0.6%, while the tech-heavy Nasdaq added 0.67%.
Heading into today, shares of the drugmaker had gained 3.48% over the past month, out... | In the latest trading session, AbbVie (ABBV) closed at $157.54, marking a -0.3% move from the previous day. Investors will be hoping for strength from AbbVie as it approaches its next earnings release. Investors should also note any recent changes to analyst estimates for AbbVie. | Click to get this free report AbbVie Inc. (ABBV) : Free Stock Analysis Report To read this article on Zacks.com click here. In the latest trading session, AbbVie (ABBV) closed at $157.54, marking a -0.3% move from the previous day. Investors will be hoping for strength from AbbVie as it approaches its next earnings rel... | AbbVie is holding a Zacks Rank of #3 (Hold) right now. In the latest trading session, AbbVie (ABBV) closed at $157.54, marking a -0.3% move from the previous day. Investors will be hoping for strength from AbbVie as it approaches its next earnings release. | In the latest trading session, AbbVie (ABBV) closed at $157.54, marking a -0.3% move from the previous day. Investors will be hoping for strength from AbbVie as it approaches its next earnings release. Investors should also note any recent changes to analyst estimates for AbbVie. |
22,690 | 2023-03-27 00:00:00 UTC | Guru Fundamental Report for ABBV | ABBV | https://www.nasdaq.com/articles/guru-fundamental-report-for-abbv-6 | null | null | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the ... | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the ... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanr... |
22,691 | 2023-03-27 00:00:00 UTC | The Zacks Analyst Blog Highlights Sanofi, Regeneron, AbbVie, Roche and Eli Lilly | ABBV | https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights-sanofi-regeneron-abbvie-roche-and-eli-lilly | null | null | For Immediate Release
Chicago, IL – March 27, 2023 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Sanofi SNY, Regeneron REGN, ... | AbbVie’s phase II study evaluating Rinvoq (upadacitinib) for patients with moderately to severely active systemic lupus erythematosus (SLE) met the primary endpoint in the 30 mg group. AbbVie also announced positive data from a phase III induction study evaluating Skyrizi (risankizumab) to treat moderately to severely ... | Here are highlights from Friday’s Analyst Blog: Pharma Stock Roundup: Meeting Goals, Receiving CRLs This week, Sanofi and partner Regeneron’s blockbuster medicine, Dupixent succeeded in a pivotal study for yet another new indication, chronic obstructive pulmonary disease (COPD).The FDA declined to approve AbbVie’s Park... | Here are highlights from Friday’s Analyst Blog: Pharma Stock Roundup: Meeting Goals, Receiving CRLs This week, Sanofi and partner Regeneron’s blockbuster medicine, Dupixent succeeded in a pivotal study for yet another new indication, chronic obstructive pulmonary disease (COPD).The FDA declined to approve AbbVie’s Park... | Here are highlights from Friday’s Analyst Blog: Pharma Stock Roundup: Meeting Goals, Receiving CRLs This week, Sanofi and partner Regeneron’s blockbuster medicine, Dupixent succeeded in a pivotal study for yet another new indication, chronic obstructive pulmonary disease (COPD).The FDA declined to approve AbbVie’s Park... |
22,692 | 2023-03-27 00:00:00 UTC | BioNTech Is Ripe For A Rebound In 2023 | ABBV | https://www.nasdaq.com/articles/biontech-is-ripe-for-a-rebound-in-2023 | null | null | BioNTech (NASDAQ: BNTX) got a substantial boost from the pandemic and its mRNA vaccine, developed with Pfizer (NYSE: PFE). The stock has seen a substantial correction since then due to slowing COVID sales, but the bottom is in. While COVID sales have slowed, this company is not dependent on COVID for its bread and butt... | AbbVie (NYE: ABBV) and Merck (NYSE: MRK) are already struggling with biosimilar compounds competing with Humira and Januvia, and others, like Bristol-Meyers Squibb (NYSE: BMY)/Pfizer’s Eliquis and Merck’s Keytruda, are fast approaching theirs. BioNTech (NASDAQ: BNTX) got a substantial boost from the pandemic and its mR... | AbbVie (NYE: ABBV) and Merck (NYSE: MRK) are already struggling with biosimilar compounds competing with Humira and Januvia, and others, like Bristol-Meyers Squibb (NYSE: BMY)/Pfizer’s Eliquis and Merck’s Keytruda, are fast approaching theirs. BioNTech’s Q4 earnings release included an update to the pipeline, making it... | AbbVie (NYE: ABBV) and Merck (NYSE: MRK) are already struggling with biosimilar compounds competing with Humira and Januvia, and others, like Bristol-Meyers Squibb (NYSE: BMY)/Pfizer’s Eliquis and Merck’s Keytruda, are fast approaching theirs. BioNTech Is A Takeover Target In 2023 The stock is trading at a ridiculously... | AbbVie (NYE: ABBV) and Merck (NYSE: MRK) are already struggling with biosimilar compounds competing with Humira and Januvia, and others, like Bristol-Meyers Squibb (NYSE: BMY)/Pfizer’s Eliquis and Merck’s Keytruda, are fast approaching theirs. Not only does it have a growing pipeline of drugs and candidates in the pipe... |
22,693 | 2023-03-27 00:00:00 UTC | Amgen-Sanofi patent case divides makers of antibody drugs | ABBV | https://www.nasdaq.com/articles/amgen-sanofi-patent-case-divides-makers-of-antibody-drugs | null | null | By Patrick Wingrove
March 27 (Reuters) - Amgen Inc's AMGN.O battle with Sanofi SASY.PA and Regeneron REGN.O at the U.S. Supreme Court over its cholesterol drug Repatha on Monday has some drugmakers hoping a ruling will reshape U.S. patent law and competition among companies that make antibody medicines.
In the dispute ... | Amgen, supported at the Supreme Court by AbbVie ABBV.N, Bristol Myers Squibb BMY.N and GSK GSK.L, wants the high court to rule that it can use “genus claims,” which describe a set of characteristics or features common to a group, to describe what Repatha does in broad language. By Patrick Wingrove March 27 (Reuters) - ... | Amgen, supported at the Supreme Court by AbbVie ABBV.N, Bristol Myers Squibb BMY.N and GSK GSK.L, wants the high court to rule that it can use “genus claims,” which describe a set of characteristics or features common to a group, to describe what Repatha does in broad language. By Patrick Wingrove March 27 (Reuters) - ... | Amgen, supported at the Supreme Court by AbbVie ABBV.N, Bristol Myers Squibb BMY.N and GSK GSK.L, wants the high court to rule that it can use “genus claims,” which describe a set of characteristics or features common to a group, to describe what Repatha does in broad language. By Patrick Wingrove March 27 (Reuters) - ... | Amgen, supported at the Supreme Court by AbbVie ABBV.N, Bristol Myers Squibb BMY.N and GSK GSK.L, wants the high court to rule that it can use “genus claims,” which describe a set of characteristics or features common to a group, to describe what Repatha does in broad language. In the dispute with Sanofi and partner Re... |
22,694 | 2023-03-25 00:00:00 UTC | Better Buy: AbbVie vs. Johnson & Johnson | ABBV | https://www.nasdaq.com/articles/better-buy%3A-abbvie-vs.-johnson-johnson | null | null | AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ) did something many other stocks didn't last year. They outperformed the S&P 500 index.
These pharmaceutical giants defied the bear market as investors favored the safety of healthcare. After all, even in a difficult economy, people generally still need their medicat... | AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ) did something many other stocks didn't last year. This year, though, AbbVie and J&J aren't off to a strong start. The case for AbbVie I've got some good news and some bad news about AbbVie. | The company's mega-blockbuster immunology drug, Humira, recently started facing competition in the U.S. And AbbVie predicts that this will result in a 37% decline in the drug's sales this year. AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ) did something many other stocks didn't last year. This year, though, Abb... | AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ) did something many other stocks didn't last year. The company's mega-blockbuster immunology drug, Humira, recently started facing competition in the U.S. And AbbVie predicts that this will result in a 37% decline in the drug's sales this year. This year, though, Abb... | The company's mega-blockbuster immunology drug, Humira, recently started facing competition in the U.S. And AbbVie predicts that this will result in a 37% decline in the drug's sales this year. AbbVie or J&J? * They just revealed what they believe are the ten best stocks for investors to buy right now... and AbbVie was... |
22,695 | 2023-03-24 00:00:00 UTC | Guru Fundamental Report for ABBV | ABBV | https://www.nasdaq.com/articles/guru-fundamental-report-for-abbv-5 | null | null | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the ... | Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the ... | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ABBVIE INC ABBV Guru Analysis ABBV Fundamental Analysis More Information on Partha Mohanr... |
22,696 | 2023-03-24 00:00:00 UTC | Pharma Stock Roundup: SNY's COPD Study Meets Goal, ABBV Parkinson's Drug Gets CRL | ABBV | https://www.nasdaq.com/articles/pharma-stock-roundup%3A-snys-copd-study-meets-goal-abbv-parkinsons-drug-gets-crl | null | null | This week, Sanofi SNY and partner Regeneron’s REGN blockbuster medicine, Dupixent succeeded in a pivotal study for yet another new indication, chronic obstructive pulmonary disease (COPD).The FDA declined to approve AbbVie’s ABBV Parkinson’s disease (PD) therapy, ABBV-951. Roche RHHBY entered into a deal with Eli Lilly... | AbbVie’s phase II study evaluating Rinvoq (upadacitinib) for patients with moderately to severely active systemic lupus erythematosus (SLE) met the primary endpoint in the 30 mg group. AbbVie also announced positive data from a phase III induction study evaluating Skyrizi (risankizumab) to treat moderately to severely ... | AbbVie’s phase II study evaluating Rinvoq (upadacitinib) for patients with moderately to severely active systemic lupus erythematosus (SLE) met the primary endpoint in the 30 mg group. Click to get this free report Regeneron Pharmaceuticals, Inc. (REGN) : Free Stock Analysis Report Sanofi (SNY) : Free Stock Analysis Re... | This week, Sanofi SNY and partner Regeneron’s REGN blockbuster medicine, Dupixent succeeded in a pivotal study for yet another new indication, chronic obstructive pulmonary disease (COPD).The FDA declined to approve AbbVie’s ABBV Parkinson’s disease (PD) therapy, ABBV-951. Click to get this free report Regeneron Pharma... | AbbVie’s phase II study evaluating Rinvoq (upadacitinib) for patients with moderately to severely active systemic lupus erythematosus (SLE) met the primary endpoint in the 30 mg group. This week, Sanofi SNY and partner Regeneron’s REGN blockbuster medicine, Dupixent succeeded in a pivotal study for yet another new indi... |
22,697 | 2023-03-24 00:00:00 UTC | 3 Simple Ways to Supercharge Your Biopharma Investing Using Artificial Intelligence | ABBV | https://www.nasdaq.com/articles/3-simple-ways-to-supercharge-your-biopharma-investing-using-artificial-intelligence | null | null | If you're not using artificial intelligence (AI) in your investing process, you're missing out on something that could empower your decision-making unlike anything ever before. Biotech and pharma investing is quite complex, and AI is a great way to slash through the complexity to make it more understandable. And you do... | In other words, you don't need to squint at AbbVie's explanations of how its biologic therapies for ankylosing spondylitis work and whether that matters in its long-running competitive showdown with the generic biologics for the condition that are made by Merck and others. You can just ask the AI to explain it to you l... | In other words, you don't need to squint at AbbVie's explanations of how its biologic therapies for ankylosing spondylitis work and whether that matters in its long-running competitive showdown with the generic biologics for the condition that are made by Merck and others. You can just ask the AI to explain it to you l... | In other words, you don't need to squint at AbbVie's explanations of how its biologic therapies for ankylosing spondylitis work and whether that matters in its long-running competitive showdown with the generic biologics for the condition that are made by Merck and others. You can just ask the AI to explain it to you l... | In other words, you don't need to squint at AbbVie's explanations of how its biologic therapies for ankylosing spondylitis work and whether that matters in its long-running competitive showdown with the generic biologics for the condition that are made by Merck and others. You can just ask the AI to explain it to you l... |
22,698 | 2023-03-24 00:00:00 UTC | Notable Friday Option Activity: CBL, ABBV, ISRG | ABBV | https://www.nasdaq.com/articles/notable-friday-option-activity%3A-cbl-abbv-isrg | null | null | Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in CBL & Associates Properties Inc (Symbol: CBL), where a total volume of 1,070 contracts has been traded thus far today, a contract volume which is representative of approximately 107,000 underlying share... | Especially high volume was seen for the $162.50 strike call option expiring March 31, 2023, with 13,571 contracts trading so far today, representing approximately 1.4 million underlying shares of ABBV. Below is a chart showing CBL's trailing twelve month trading history, with the $25 strike highlighted in orange: AbbVi... | Below is a chart showing CBL's trailing twelve month trading history, with the $25 strike highlighted in orange: AbbVie Inc (Symbol: ABBV) options are showing a volume of 42,121 contracts thus far today. That number of contracts represents approximately 4.2 million underlying shares, working out to a sizeable 56.4% of ... | That number of contracts represents approximately 4.2 million underlying shares, working out to a sizeable 56.4% of ABBV's average daily trading volume over the past month, of 7.5 million shares. Especially high volume was seen for the $162.50 strike call option expiring March 31, 2023, with 13,571 contracts trading so... | Especially high volume was seen for the $162.50 strike call option expiring March 31, 2023, with 13,571 contracts trading so far today, representing approximately 1.4 million underlying shares of ABBV. Below is a chart showing ISRG's trailing twelve month trading history, with the $260 strike highlighted in orange: For... |
22,699 | 2023-03-24 00:00:00 UTC | AbbVie (ABBV) Provides Clinical Updates on Inflammatory Drugs | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-provides-clinical-updates-on-inflammatory-drugs | null | null | AbbVie ABBV announced multiple clinical updates pertaining to clinical studies evaluating its blockbuster drugs Skyrizi and Rinvoq for expanded use.
Management announced topline data from the phase III INSPIRE study, which evaluated Skyrizi (risankizumab) as an induction therapy in adult patients with moderately to sev... | In a separate press release, AbbVie also reported positive topline data from a phase II study (SLEek) which evaluated Rinvoq (upadacitinib), alone as well as combined with BTK inhibitor elsubrutinib, in patients with moderately to severely active systemic lupus erythematosus (SLE). AbbVie ABBV announced multiple clinic... | Click to get this free report Novartis AG (NVS) : Free Stock Analysis Report Biogen Inc. (BIIB) : Free Stock Analysis Report Amgen Inc. (AMGN) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie ABBV announced multiple clinical updates pertai... | AbbVie Inc. Price AbbVie Inc. price | AbbVie Inc. Quote Zacks Rank AbbVie currently carries a Zacks Rank #3 (Hold).You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. Click to get this free report Novartis AG (NVS) : Free Stock Analysis Report Biogen Inc. (BIIB) : Free Stock Analysis Report... | Like Amgen, several other companies like Biogen, Boehringer Ingelheim and Pfizer have also received FDA approvals for their own Humira biosimilars, many of which are expected to be launched at various times this year per agreements with AbbVie. AbbVie ABBV announced multiple clinical updates pertaining to clinical stud... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.